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The thesis objectives are to compare and evaluate the factors about reporting 
Adverse Drug Reactions in the developed and developing countries among 
healthcare professionals (Medical doctors and Pharmacists) using Ireland and Nigeria 
as a case study. Which a questionnaire survey and phone interviews for quantitative 
and qualitative analysis are carried out respectively within the two regions (Ireland 
and Nigeria). The challenges faced by medical professionals concerning ADR 
reporting are achieved based on their knowledge and awareness to determine an 
effective recommendation to help improve both regions using the comparison 
results and works of literature gathered. 
From the author results and analysis, both groups of healthcare professionals from 
the two regions were compared to determine their opinion in respect to observation 
and reporting of ADRs under the categories of under-reporting, ADR reporting 
methods, regulations and guidelines pertaining ADR report in both Ireland and 
Nigeria as HPRA and NAFDAC are the regulatory body responsible for handling 
submitted ADR reports. An Overall total of 122 respondents from both Nigeria and 
Ireland are received which consists of 47 respondents from Ireland (12 medical 
doctors and 43 pharmacists) and 75 respondents from Nigeria (32 medical doctors 
and 43 pharmacists) showing a response rate of 60.0% and 87.5% from 20 and 45 
medical doctors and pharmacist from Ireland and response rate of 71.1% and 95.5% 
out of 45 respondents respectively from both medical doctors and pharmacist from 
Nigeria. Surprisingly, 98.0% of the correspondents which consist of 12 medical 
doctors and 35 pharmacists from Ireland responded to knowing how to report ADRs 
to compare to 71.0% from Nigeria which is quite above average consisting of 26 
medical doctors and 27 pharmacists responded to knowing how ADRs is being 
reported. However, it shows that pharmacists had better knowledge, awareness, 
understanding, and experience over the medical doctors regarding ADRs reporting. 
However, 92.0% and 96.0% of respondents of both groups from Nigeria and Ireland 
respectively opted to ADR reporting being made compulsory as a professional 
obligation towards achieving and improving pharmacovigilance. 
Furthermore, the challenges affecting ADR reporting in Nigeria are associated with 
the inaccessibility of ADR report forms when needed, complex reporting processes 
while too busy and lack of time remained the most common challenging factor 
among this too regions. The least common challenges reported at both regions are 
level of clinical trial knowledge, a concern that ADR report mighty is wrong among, 
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fear of legal liabilities, and fear of exposure to legal liabilities from patient or drug 
manufacturer. 
Finally, after proper comparison and recommendation from both sides from the 
country it shows the need for better improvement in awareness among healthcare 
professionals in Nigeria been the country with the highest level of challenges 
compare to their counterpart healthcare professionals and this could be achieved by 
organizing pharmacovigilance conferences, continuous education programs included 
in their professional courses and training to improve knowledge of ADR reporting. 
Establishment of ADR departments in healthcare institutions headed by ADR 
specialists and offering professional recognition rather than financial rewards are the 
sustainable recommendation to put in practice in both regions to further improve 
the practice of ADR reporting in Nigeria and Ireland. 
To wrap it up, the need for the regulatory bodies from the developing countries to 
work in hand with the developed countries to better improves awareness, 
knowledge, and improvement towards ADRs reporting system. 
 
Key Words: Adverse Drug Reactions (ADRs): knowledge, awareness and challenges, 
Pharmacovigilance, ADR reporting systems, healthcare professionals, Nigerian Agency for 
Food and Drug Administration and Control (NAFDAC), National Pharmacovigilance Centre, 
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                                            CHAPTER ONE 
                                           INTRODUCTION 
1.0 BACKGROUND OF THE STUDY 
“Wherever the art of Medicine is loved, there is also the love of Humanity.”    
― Hippocrates  
Medicine majorly constitutes the use of prescribing and administering drugs by 
healthcare professionals majorly the pharmacist and the medical doctors. The 
importance of these two professions is very paramount in fighting diseases and 
promoting good healthcare as well as the general well-being of humans. Also, the 
current drug discovery and research within the pharmaceutical industry have led to 
the will for the need for the safety and efficacy of drug products. The safety of the 
drug has been a major concern aftermarket authorization due to limited clinical trials 
which cannot prove the safety of the public health after consumption. 
Pharmacovigilance came into existence as a result of a tragic thalidomide event that 
happens around the 1960s which has helped towards drug safety issues with the 
ability for quick response drug reporting systems with that of the risk management 
plan in place to ensure the safety of drug user. Adverse drug reaction has always 
been a major challenge in the life of drug user and this cannot be avoided but rather 
can be prevented.  
New drugs standard is maintained with the help of strict regulatory standards and 
guidelines that must be carried out during the clinical trial phases and post-
marketing. The standard clinical trial phases include phase 1 which usually comprises 
of the certain number of human mostly less than 20 and their safety with a lesser 
dosage of the drug, phase 2 is usually comes up after phase 1 has been successfully 
performed and this involves safety studies on a larger number of human between 50 
to 100 towards the adequate dosage specifications. Phase 3 is usually carried 
towards a specific condition at which the drug is being produced for the 
effectiveness in treating a certain condition while phase 4 is conducted to identify 
the long term effects of the drug after the approval and enters the market. (MS 
Research Australia, 2020) 
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Figure 1: phases of clinical trial (MS Research Australia, 2020) 
 
Figure 2: phase 4 trial (Pharmacovigilance) 
 
Furthermore, after drug production and after passing through all the phases of 
approval, licensing and releasing into the market, it has been gathered that there is 
always minimal information on such drug safety. This is not coming as a surprise as 
the number of patients used during clinical trials is relatively low compare to the 
actual population of the patients dependent on these drugs and prescriptions. This 
phase led to pharmacovigilance activities of ADR reporting to know how drug 
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1.2 Research Purpose 
This research aims to adequately tackle the challenges and help improve ADR 
reporting in the developing countries while also assessing to help analyse the level of 
understanding (knowledge), altitude and experience of ADR spontaneous reporting 
among medical professionals (Medical doctors and Pharmacist) in both countries in-
line with established regulations and guidelines by both relevant authorities. Besides, 
there is a very low spontaneous reporting practice in developing countries compared 
to that of the developed countries based on previous research studies. However, this 
has led to us looking at which area needs improvement in the developing countries 
using Nigeria as a case study and Ireland as a case study of a developed country. 
This research dissertation on current and future drug monitoring reporting was 
aimed at developing strategies from the case study of Ireland to help improve the 
quality of reporting in the developing countries towards driving a better positive 
outcome for patients across Nigeria.   
1.3 Significance of the study 
Over the years, there has been a major gap in spontaneous reporting of ADRs 
recommended in healthcare centres and hospitals in the developing countries 
(Nigeria) which has led to a major gap in the current pharmacovigilance practices 
among healthcare professionals compared to that of the developed countries 
(Ireland). So it is important to help engage and improve the challenges facing the 
developing countries, although many professionals (physician) tend to report only 
serious adverse reaction related to life threat but the challenges of delays in getting 
feedback are often a thing of dissatisfaction with the whole process used in the ADRs 
reporting management. 
The HPRA in Ireland serves as the representative for pharmacovigilance practice and 
ADRs while the National Pharmacovigilance Centre Abuja under the monitoring of 
NAFDAC serves as a drug monitoring centre which they both help in the evaluation of 
risk ratio associated with any drug prescription or over the counter drugs. So the 
need to address the factors mitigating against having an effective ADR reporting as 
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1.4 Research Objectives:  
1. To investigate the challenges affecting the role of effective ADR reports in 
developing countries using Nigeria as a case study. 
2. To examine the awareness of healthcare professionals around their parts and 
obligation in viably announcing ADRs in Sub-Saharan Africa 
3. To collect and review guidelines and regulations about proper drug delivery and 
monitoring in developed countries (EU) using Ireland as a case study. 
4. To review the guidelines and regulations about ADR in Sub-Sahara Africa. Also, 
giving recommendations and how to improve the reporting of ADRs among the 
developing countries.  
5. Comparative assessment of drug monitoring for the above-stated countries and 
how we can use that of the developed countries method to improve that of 
developing countries. 
 Research Questions: 
1. Are the healthcare professionals aware of ADR reporting system methods and 
their responsibility towards good pharmacovigilance practice in Nigeria and Ireland? 
2. What factors pose as challenges to ADR reporting in Nigeria and Ireland? 
3. What is the level of awareness among healthcare professionals in Ireland   and 
Nigeria in relation to ADR announcements? 
4.  What are the similarities and differences towards ADRs reporting among HCPs in 
Nigeria and Ireland? 
5. What recommendations would help to improve ADR reporting among healthcare 
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1.5 Structure of the study 
The structure of this dissertation was to be carried out based on a qualitative 
approach with the use of surveys and questionnaires and qualitative approach using 
phone interviews. 
These questionnaires were designed majorly for the medical doctors and 
pharmacists. This reason was a result of medical doctors are in charge of prescription 
of drugs at various medical teaching hospitals and healthcare centres while the 
pharmacist is in charge of dispensing of prescribed drugs in the healthcare centres or 
community pharmacy. 
Each questionnaire is divided into five sections where each questionnaire is sent to 
both countries (Ireland and Nigeria) for respective feedback. 
Section 1 is based on demographics containing age, experience, and occupation. 
Section 2 is based on information and level of knowledge on ADR reporting in both 
Ireland and Nigeria. 
Section 3 is based on countries' awareness of ADRs. 
Section 4 based on factors that serve as challenges facing ADR reporting in each 
region. 
Section 5 based on factors that can help improve the challenges an ADR reporting in 
Nigeria and Ireland. 
A qualitative study was carried out by conducting phone interviews with healthcare 
professionals in Nigeria and Ireland to have a better experience and their opinion 
regarding ADR reporting in both countries, which the result obtained above from 
both the quantitative and qualitative are used to obtain a balanced conclusion on the 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Overview 
Over the years, a lot of studies have being carried out on ADRs and 
pharmacovigilance but in this chapter the author will be covering both old and recent 
research and studies that have to do with ADRs reporting and pharmacovigilance 
among HCPs and what are the root cause, while some countries and most especially 
the developing world are still faced with the challenges of poor reporting system.   
2.2 CONTEXT 
According to the World Health Organisation on pharmacovigilance relating to the 
activities of detection, assessment, understanding, and prevention of adverse effects 
or any other drug-related problem. Also, the key roles in ensuring the patients 
receive safe drugs and the need for intensive monitoring and the need for new 
processes to help review and discuss the new methodological approach. (Härmark 
and van Grootheest, 2008).  
Moreover, pharmacovigilance is checking for the effect of drug products which also 
include the characteristics of such drug towards treating a particular disease a 
process known as pharmacodynamics effects which are usually documented in 
animal studies during phase 1 and phase 11 studies in humans and phase 111 clinical 
trial (Montastruc et al., 2006). This led to pharmacovigilance activities which include 
ADR reporting starting with patients (children, young adults, and the elderly ones) 
receiving drug therapies to be able to identify how to reduce the rates of adverse 
reactions from patients  
Besides, the World Health Organisation defines drug reaction as ‘‘an unpleasant 
reaction which occurs as a result from an interventional related to the use of drug 
products during therapy of disease.’’ Besides, adverse drug reaction reporting can 
become serious when there are occurrence medical conditions as a result of a 
particularly given dosage which leads to patient hospitalization, remarkable 
incapacitation or disability, life-threatening or even deaths. ADRs can be grouped 
into three major groups which can either be Minor; where there is no therapeutic or 
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hospitalization extension, intervention or antidote. Moderate; usually involve a 
change in current drug therapy where alternative treatment is recommended and 
this usually requires more days in hospitalization. Serious/Lethal; this is usually a life-
threatening stage and requires urgent medical attention and intervention which can 
result in temporary or permanent damage or even death.  
Over time, researchers have been able to come up with the classification of ADRs 
1. Type A reactions – also known as augmented (dose-related) reactions which 
are usually related to any form of the pharmacological action and usually 
comes with a low mortality rate. Besides, they are easily preventable and 
predictable. Common examples in these categories include side effects such 
as anticholinergic of tricyclic antidepressants, haemorrhage associated with 
the use of anticoagulants, etc. 
2. Type B reactions- also known as bizarre (not dose-related) reactions which are 
usually not common and not related to any form of pharmacological 
mechanisms of the drug. In contrast with type A which has a low mortality 
rate, the rate of mortality for this type is quite higher and very unpredictable. 
Examples include idiosyncratic reactions such as acute porphyria, malignant 
hyperthermia and pseudoallergy (ampicillin rash). 
3. Type C reactions- These are referred to as chronic dose-related and time-
related reactions. They are side effects that occur as a result of drug 
accumulation over a long period. Some examples include corticosteroid 
treatment resulting in organ damage. 
4. Type D reactions-also called delayed reactions which are usually uncommon 
but occur sometime after the use of the drug. Such examples are seen in the 
use of tetracycline which later causes discoloration in the teeth, also in 
carcinogenesis and tardive dyskinesia. 
18 | P a g e  
 
5. Type E reactions- usually classified as End of the use reactions which occur 
mostly after the withdrawal of the drug. Such examples include myocardial 
ischemia also known as a beta-blocker withdrawal, rebound hypertension 
after a centrally acting antihypertensive drug. 
6. Type F reactions- also know has a Failure reaction which is very common and 
often caused by drug interactions between two or more drugs. Such an 
example usually includes an inadequate dosage of an oral contraceptive, 
particularly when used with specific enzyme inducers. (Edwards and Aronson, 
2000) 
So, to eradicate ADRs' impact on the public well-being of patients, the introduction 
of pharmacovigilance came into reality in the healthcare sector. According to the 
World Health Organisation who defines ‘’pharmacovigilance as the science and 
activities relating to the detection, assessment, understanding, and prevention of 
adverse events or any other medical-related issue’’ where the main purpose is to help 
in patient safety by helping with the use of medicinal products.   
2.3 REGULATORY AUTHORITIES 
The safety of drugs is ensured by several regulatory authorities in different countries 
and regions; this is done to make sure that there is a safe and efficacious drug at the 
highest attainable quality to the public. This is usually done at several stages of 
operation starting from the implementation of pharmaceutical regulations related to 
product registration, manufacturing, pricing, operation excellence, research and 
development, and intellectual data protection. Doing this will help protect the 
patient from any undue side effect by easily identification of any form of 
predisposing factors while also countering false safety signals from any form of 
spontaneous reporting or case studies published report.(Sengar and Tripathy, 2011) 
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COUNTRY REGULATORY AUTHORITY 
Nigeria 
National Agency for Food and Drug Administration and Control 
(NAFDAC) 
UK Medicines and Healthcare Products Regulatory Agency (MHRA) 
USA Food and Drug Administration (FDA) 
Ireland  Health Products Regulatory Authority (HPRA) 
Canada  Health Canada 
Europe European Medicines Agency (EMEA) 
Netherlands Medicines Evaluation Board 
India Central Drug Standard Control Organisation (CDSCO) 
Italy  Italian Pharmaceutical Agency 
Singapore Centre for Pharmaceutical Administration Health Sciences 
Authority 
Hong Kong Department of Health: Pharmaceutical Services 
Sweden Medical Products Agency (MPA) 
China State Food and Drug Administration 
Germany Federal Institute for Drugs and Medical Devices 
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Malaysia National Pharmaceutical Control Bureau, Ministry of Health 
South Africa Medicines Control Council 
Uganda Uganda National Council for Science and Technology (UNCST) 
Japan Ministry of Health, Labour & Welfare (MHLW) 
INTERNATIONAL ORGANISATIONS 
World Health Organisation (WHO) 
Pan American Health Organisation (PAHO) 
International Conference on Harmonisation (ICH) 
World Intellectual Property Organisation (WIPO) 
Table 1: International Organisation and Regulatory Authorities  (Sengar and Tripathy, 
2011) 
The mentioned above regulatory came into existence as a result of the thalidomide 
effect which influences the world towards drug safety as for the efficacy as well. This 
led to the world health organization member countries towards establishing national 
pharmacovigilance centres where healthcare professionals can send individual cases 
of drug safety and the centre is situated at Uppsala Monitoring Centre, WHO 
Collaborating Centre for International Drug Monitoring, Uppsala, Sweden(Edwards 
and Aronson, 2000). Moreover, WHO program includes a list of several member 
countries including Nigeria who joined in the year 2004 and according the first 
published regulations in 2005 which states that every healthcare institution with 
patients beds of 50 upward patients must ensure to employ the use of a 
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pharmacovigilance centre who serves as a reporting centre for any form of ADRs 
while also promoting and educating healthcare professionals towards reporting any 
suspected or serious form of ADRs. Although, there are several possible ways of 
creating awareness for ADRs, despite that spontaneous reporting has been the major 
and basic method of ADR detection which has helped over the decades but the major 
challenges facing this is the under-reporting by healthcare professionals (Montastruc 
et al., 2006).  
For instance, the UK system makes use of yellow cards as their mode for reporting 
ADRs which has contributed to better the standards of pharmacovigilance(Felix et al., 
2019).     
Also, recent and previous studies have shown a high level of the importance of 
healthcare professionals as it concerns the spontaneous reporting of ADRs towards a 
build-up of the pharmacovigilance database. Besides, under-reporting of ADR has 
been one of the major challenges of spontaneous reporting even though previous 
studies have established that these responsibilities lie mainly with the medical 
doctors who prescribe the medications while some other studies also claim the 
pharmacist and other healthcare professionals also have a vital role to play as well. 
Lack of sufficient knowledge and follow of guidelines and regulations related to ADR 
has led to the confusion of who bears the major responsibility of ADR reporting 
among the healthcare professionals. 
Furthermore, there is a need to increase drug monitoring in poor countries, which 
bear 90percent of the global disease burden. Although most drugs developed are 
extensively developed and used within the developed countries where there is a 
high-level global practice, using this safety profile in the developed countries cannot 
necessarily be generalized to developing countries because this occurrence, pattern, 
and harshness adverse reactions may differ markedly because of local environmental 
and genetic influences. Due to this, the WHO program for international drug 
monitoring has led to the centre set up to help collates adverse drug reaction reports 
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via the national pharmacovigilance centres of the 81 member countries (www.who-
umc.org). However, currently, only six sub-Saharan African countries (South Africa, 
Zimbabwe, Tanzania, Mozambique, Nigeria, and Ghana) are full members of the 
program. Less than 27% of lower middle income and low-income economies have 
national pharmacovigilance systems registered with the WHO program, compared 
with 96% of the high-income countries in the Organisation for Economic Co-
operation and Development. The main reasons for this are lack of resources, 
infrastructure, and expertise. Thus, although access to medicines is increasing in 
developing countries, there is a danger that their risk-benefit profiles in indigenous 
populations will not be fully monitored and acted upon. So what can be done to 
improve drug safety monitoring in developing countries? (Pirmohamed et al., 2007). 
Pharmacovigilance: As per World Health Organization (WHO), “Pharmacovigilance is 
the science and exercises relating to the discovery, evaluation, understanding 
and avoidance of antagonistic impacts or any other medicate related 
problems”. Shockingly, when this term is said, it is exceptionally much a case of 
“Pharmaco what?” There's still a need of understanding on this theme like how 
it capacities, what are the benefits of sharing ADR information and 
its reason and significance. In addition, Adverse drug reaction” or an “adverse 
reaction” implies a reaction to a medication within the people or creatures, which is 
harmful and unintended, counting need of adequacy, and which happens at any 
measurement and can too result from an overdose, abuse or manhandle of a 
pharmaceutical drug (Yadav, 2008). 
On the other hand, the term “post-marketing observation (PMS) study” infers an 
experimentally thorough consider of an item that's affirmed for enlistment in a 
specific nation, outlined to deliver solid data around drug safety. It isn't suitable to 
apply the term to clinical trials of enlisted items or to considers planned basically for 
showcasing purposes notwithstanding of the logical legitimacy of the think about 
plan. Post-marketing observation considers are for the most part performed on the 
activity of the supporting company but may be proposed or asked by other parties. 
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They ought to by and large be outlined to address a sedate security address or 
speculation (the last mentioned regularly recognized at first by intentional detailing). 
Also, the Nigerian National Bureau of Statistics has shown records of life expectancy 
rates in the country to be lowest among the other West African countries while the 
World Health Organisation estimated it to be around 54.5 years of age. These values 
attributed to the health issues faced by the country with a high level of mortality 
rates. Although, irrespective of all these challenges, the country still has a faster 
population growth rate of about 2.6% which is projected to have over 390 million 
people by the year 2050. (World Population Review, 2020) 
 
 
Figure 3: : Infant Mortality rates In Nigeria compare to other developing Africa 
countries (Alemu, 2017) 
 
2.4 Pharmacovigilance and Adverse Events Reporting in Ireland. 
European Union has always made changes to pharmacovigilance legislation which 
has always include additional monitoring of medicines which aim to help speed up a 
positive result from adverse drug reaction reporting systems. This legislation has also 
helped in the easy traceability of our medicine. The European Union legislation on 
pharmacovigilance as laid down directives which are to further help in protecting the 
public health by strengthening the monitoring system and these directives are 
Directive 2001/83/EC and Regulations (EC) No 726/2004. Some of the 
implementations are in the area of operation which gives details on the guidance of 
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the number of good pharmacovigilance practice (GVP) modules to help facilitate the 
performance of pharmacovigilance in the European Union. (HPRA) 
Good Vigilances Practices (GVP) Good Pharmacovigilance practices (GVP)  are 
measure put in place to help facilitate the performance of pharmacovigilance in 
Europe Union and this measure are used in the areas of marketing authorization 
holders, European medicines Agency and regulatory authorities in the EU member 
states. (HPRA). In Ireland, market authorization holders must ensures that there is 
appropriate approval of the market product through thorough pharmacovigilance 
system in place to be able to take up responsibility for the marketed medicines and  
inspections will be carried out on daily basis by the HPRA .  
Pharmacovigilance Inspections in Ireland. 
• Pharmacovigilance inspections in Ireland are carried out to determine that the 
market authorization holder has the necessary equipment and facilities in 
place to meet the obligation laydown by HPRA. Besides, it also helps in easy 
identification and record-keeping of any form of non-compliance which may 
pose any risk to the public.  
• Different types of inspections                                                         
• Pharmacovigilance system inspections: this is designed to review the 
procedures, systems, personnel and facilities used in carrying out compliance 
concerning regulatory obligations.                          
• Product-related pharmacovigilance inspections:  this focused more on 
product-related issues including product-specific activities and documentation 
rather than making use of system review even though this does not stop using 
the system review along the process.                                                                
Routine inspections: This inspection is carried out based on the risk 
assessment approach in advance as part of the inspection programs.   
• For cause inspection: this is done as a result of information or report which 
need to be inspected in a way to examine the issue.                                           
Pre-authorization inspections: usually performed to verify the accuracy and 
successful implementation of the pharmacovigilance system.                     
Notification of Inspection: This is usually carried out by the pharmacovigilance 
service provider where they get notification within four to six weeks before 
the proposed inspection date. And information such as  
• An updated version of the pharmacovigilance system master file 
• Company organization charts and the role of key personnel involved in the 
pharmacovigilance activities. 
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• Cases of adverse events 
• Data Collection systems list. 
• Risk Management Plans and Safety Update Report. 
• List of Safety variations submitted 
• Approved reference safety information(e.g. summary of product 
characteristics SmpCs).(HPRA) 
• For a publication titled adverse drug reaction reporting: opinions and 
attitudes of medical practitioners in Ireland which discuss how the safety of 
drugs in clinical trials practice is being carried out with a 15percent of it being 
reported where a study of about 207 doctors was carried out which shows 
that most doctors (97%) in Ireland were not certain about the purpose of 
reporting scheme while (52%) were uncertain about the availability of report 
forms and (28%) of them agree to be busy or not certain of the importance of 
the form. Besides, (90%) of the Doctors agree for improvement and 
continuous awareness and education about the importance of reporting 
ADRs.(McGettigan and Feely, 1995) 
 
Another publication with the title knowledge of Adverse Drug Reaction Reporting 
and the Pharmacovigilance of Biological Medicines: A survey of healthcare 
professionals in Ireland where the objectives of the study are to assess the level of 
knowledge and general experience and attitudes towards ADR reporting where 86% 
of the pharmacist claimed to have a higher awareness of ADR compared with that of 
Doctors with 35.1%.(O’Callaghan et al., 2018) 
In conclusion and comparison of the two stated publications, it shows the 
importance of pharmacists in the area of ADR reporting while the Doctors need more 
pharmacovigilance awareness while also improving the system support for easy 
feedback of ADR reporting.  
Besides, the need for ADR reporting is very important to help reduce the mortality 
rate within the country. According to the Department of health in the year, 2016 
where 52.9% of the men and 53.5% of the women are reported to be aged 65 are 
said to have a different chronic illness or other health problems(Hilliard, 2017). The 
stated above shows the need for more healthcare demands which require proper 
monitoring and reporting of any form of ADRs  needed to understand the safety of 
drug practices. 
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2.5 Pharmacovigilance and Adverse Events Reporting in Nigeria. 
As earlier discuss that adverse events is an overview of any harm that occurs to any 
patient during drug administration which can temporarily be associated with the use 
of a therapeutic or a medicinal products but may be the actual real cause of the 
medical occurrence. A very good example of adverse events is adverse drug reactions 
(ADRs) which are defined as any undesired effects of the drug that occur during 
dosage intake for prevention or treatment.(Okezie and I., 2008) 
The current declining healthcare standards in Nigeria and an increase in the 
population of about 200 million make the ADRs reporting ineffective which has been 
a major challenge in Nigeria and developing countries as a whole. Financial benefit 
and remuneration with an inadequate workforce of healthcare professionals 
continue to be a major hamper in having a good pharmacovigilance practice and as a 
result, ADRs reporting become a major problem in clinical practice which also 
backfires in implementing the WHO guidelines and regulations in related to 
pharmacovigilance. Another major challenge is the unavailability of advanced 
healthcare facilities and technology also constitutes the problems facing the 
implementation and effective ways of ADR reporting. 
Furthermore, research also shows that drugs used in the treatment of chronic 
diseases, treatment of pain relief and to improve health conditions are important in 
the healthcare system. However, this most common drug has cause various side 
ADRs such as drowsiness, oedema, headache, fatigue, diarrhoea, and vomiting while 
some are reactions from neurological conditions, dermatological reactions and 
gastrointestinal reactions. A sample publication titled pattern of medications causing 
adverse drug reactions and the predisposing risk factors among medical in-patients 
in clinical practice: a prospective study, here the author established where the body 
organ system is usually affected by ADRs where the neurological system has the most 
affected system with about 33.3% followed by a gastrointestinal system of about 
21.6%,17.6% dermatological system, the cardiovascular system of 7.85% in  40 
patients and finally the endocrine and the respiratory which were equal with 3.9% 
patients each.(Akhideno et al., 2019)  




Figure 4:  Medications causing adverse drug reactions among medical 
inpatients in a Nigerian Teaching Hospital from December 2013 to August 
2014. (Akhideno et al., 2019) 
 
Figure 5:   ADR involvement and frequency of body organ/system affected the most. 
(Akhideno et., 2019) 
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2.6 Pharmacovigilance and ADR reporting. 
As earlier discussed that pharmacovigilance is activities that help in detecting, 
assessing or preventing any form of drug-related issue or any drug associated with 
any adverse events. The combination of epidemiological studies and a clinical trial 
has been a major contribution to the pharmacovigilance studies and ADR reporting. 
Besides, the reason for the establishment of the pharmaceutical industry is to 
provide well-being for the public suffering from any health-related issues and in line 
with the proper regulatory bodies the safety of drugs will be put into consideration. 
Good pharmacovigilance and post-marketing surveillance have been the major 
factors helping to improve patient health outcomes and contribute towards future 
drug research and development and also in the area of clinical trial and 
coordination.(Talbot and Nilsson, 2002) 
For instance, a published article on the evaluation of awareness about 
pharmacovigilance and adverse drug reaction monitoring in resident Doctors while 
also suggesting possible ways to improve it. This publication shows the importance 
and the correlation between pharmacovigilance and ADR and the associated risk 
factors that occur due to under-reporting among healthcare professionals while also 
stating the reason to improve on the knowledge of the HCP about 
pharmacovigilance. Using a questionnaire-based survey where the respondents are 
resident doctors who provided all information bases on ADR reporting which were 
considered for analysis. The questionnaire response rate was quite high with about 
93.3% from 84 questionnaires while 64.3% admitted to the awareness of 
pharmacovigilance, 52.4% were also aware of ADR reporting system in India, 83.4% 
suggested that only serious ADR in related to medicine should be reported, 35.7% 
believed that only newly produced medicine should be reported even though 68% of 
the respondent only observed an ADR while only 25% tend to report and ADR. 
Besides, 8.3% believed that there is a need to improve cooperation among 
healthcare practitioners and pharmacovigilance authority. From the results, the 
author concluded that there is a need for an increase in awareness of 
pharmacovigilance and collaboration within the stakeholders to help improve ADR 
reporting.(Pimpalkhute et al., 2012)    
The case of thalidomide disaster in the 1960s leads the development of the national 
pharmacovigilance system among the developed countries which most use the 
spontaneous reporting and other pharmacoepidemiological methods to collect and 
analyse any form of problems associated with drug usage. In addition, every 
developed country developed its pharmacovigilance national system which 
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contributes to the global database such as the one held at the Uppsala Monitoring 
centre and doing this will need an extensive and costly infrastructure. In a case of the 
developing countries where healthcare resources are limited, funding and engaging 
in infrastructural development in such areas can be challenging. For instance,    
funding system for the pharmacovigilance program in the US tends to work because 
of the stakeholders ready to work together compare to that of the developing 
countries because during this will lead to increase in drug costs which will alter the 
rate of increasing access to medicine while affecting pharmacovigilance and ADR 
reporting at the long-run. But the WHO needs to work things out between the 
stakeholders by making them come together to develop a model that will support 
pharmacovigilance activities in the developing countries which can be done with 
proper developing of exchange programs between the developed countries and the 
developing countries to help improve their level of awareness, knowledge and local 
expertise in the area of pharmacovigilance.(Pirmohamed et al., 2007)  
Spontaneous reporting systems are widely adopted for pharmacovigilance most 
especially when the ADR is rare and common (<1%) and most importantly when it is 
drug-related condition. Clinical Practice Research Datalink (CPRD) presents an 
opportunity to be able to analyse and expose any form of potential adverse events in 
the databases. Some other drug safety data used in the pharmacovigilance studies 
include published data, pharmaceutical company data from proper updates from the 
periodic drug safety update reports and data shared intentionally.(Coleman and 
Pontefract, 2016) 
2.7 Who is responsible for Reporting Adverse Drug Reactions? 
The medical doctors and pharmacists are the main healthcare professionals 
responsible for reporting ADRs observed during their practice and involvements with 
patients showing symptoms. A survey conducted by the European Commission 
shows that 5.0% of hospital admissions are due to ADRs while the patients 
experience an ADR while on admissions. Also, according to the EC, about 200,000 
patients’ mortality is usually a result of ADRs which now represent the fifth most 
common cause of death within the European Union. About £80 billion is the most 
budgeted healthcare burden for ADRs in the EU as in 2008 (Giardina et al., 2018). The 
study of medicine safety is usually associated with the clinical trial carried out on it 
and this is usually limited until the drug is being introduced to the public for 
marketing,  which led to needing for the importance of reporting any form of ADRs 
among healthcare professionals to be able to carry out further research on drug 
investigation(HPRA, 2020) 
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In Ireland, where Health products regulatory Authority (HPRA) oversees the 
operation of national adverse drug reaction reporting and monitoring of drug safety. 
During the drug monitoring process which involves gathering and collecting data for 
proper updating on drug labelling, drug risk patterns while also encouraging other 
investigators to prevent these drug reactions. This information gathered helps in 
making research and improvement needed to be done positively while also serves as 
a modality that guides researchers, healthcare professionals, and pharmaceutical 
companies.(Council for International Organisations of Medical Sciences, 2000)  
The earliest healthcare professionals to always have contact with patients either 
community pharmacist or in hospital settings are the Medical doctors and 
Pharmacists. They are also expected to report any case of ADRs from any drug newly 
authorize into the market and any old drug products which have been included to be 
among the drug monitoring list after their approval. Due to all these mentions above, 
led to the importance of drug safety assessments among the healthcare 
professionals during their routine when dealing with patients.(HPRA, 2020) 
2.8 Challenges Faced Among Healthcare Professionals in Reporting Adverse Drug 
One of the most challenges faced in reporting an ADR is usually the language of 
reporting as most clinicians tend to communicate orally with one another and when 
dealing with patients. But in a case of reporting there is always a problem of 
understanding some of the terminologies because the clinicians tend to define a 
clear case of ADRs or well-known diseases compare to the use of the term in 
reporting.(Council for International organizations of Medical Sciences, 2000) 
A sample research article titled perception of doctors to adverse drug reactions 
reporting in teaching hospital in Lagos, this research was aimed to evaluate the level 
of understanding of healthcare professionals towards ADRs reporting where a total 
120 medical doctors were evaluated using a questionnaire to ascertain their 
knowledge and attitude towards ADR reporting and some of the challenges face that 
resulted in the under-reporting of ADRs are associated with legal actions which 
involve the fear of litigation, financial incentives associated with professional 
activities and the belief that a drug has already been well examined before 
authorization for marketing. Besides, the mentality of indifference that a single ADR 
reporting does not have any effect on medical knowledge or to national drug safety 
practice, which led the ignorance of believing that only serious life-threat related 
drugs should be reported. Another factor is procrastination and lack of enthusiasm 
towards ADR reporting or lack of time or will towards reporting a case of ADR 
(Oshikoya and Awobusuyi, 2009) 
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Furthermore, apart from the mentioned above global issues affecting ADR reporting 
within the healthcare professionals who are mostly related to that of lethargy and 
insignificant contribution. Taking a case study of developing countries using Africa for 
instance where the factors resulting to low ADR reporting has not been studied 
because according to the author which stated that only two studies have been 
attempted towards analysing the factors facing under-reporting in African countries 
which they both indicate lack of adequate knowledge among health professionals. 
This research was carried out using a questionnaire where 82% respondent are 
gotten and 89% considered the most qualified among the doctors to report ADRs, 
only 40% were aware of National Pharmacovigilance Centre in Nigeria, 32% claim to 
be aware of yellow card reporting scheme while only 48.5% believe reporting of ADR 
can only be done when the drug has been licensed, authorized and marketed. This 
resulted in differences among the respondent who believe in ADR reporting should 
be compulsory to that of those who opposed it being voluntary.(Oshikoya and 
Awobusuyi, 2009) 
The study concluded that there is the inadequacy of knowledge of medical doctors 
regarding ADRs reporting which is common among the Doctors not just in developing 
countries but also in developed countries. This research highlighted the need for an 
improvement in awareness and proper medical training towards pharmacovigilance 
while also educating and training other health professionals on spontaneous 
reporting and the use of yellow cards. Although reporting of ADR was highly 
recommended by the National Pharmacovigilance Centre most health professionals 
see it as unrecognized while some percentages are not even aware of the existence 
of NPC even though 39% are aware of the office of NPC location which happens to be 
in Abuja. Base on this, without proper awareness and knowledge of where to report 
ADRs, the prevailing rate of reporting will continue to remain poor. The agency which 
happens to be NAFDAC must ensure a guideline and enforcement towards ADRs 
among healthcare professionals so has to improve the ADR reporting.(Oshikoya and 
Awobusuyi, 2009) 
Over a decade ago, a study was carried out in Ireland on ADRs reporting among 
hospital doctors who involve a total of 118 doctors where only 45% had ever 
reported a case of ADR and fewer than 5% of pre-registration house officers had 
reported an ADR which also shows that rate of reporting was highly associated with 
the level of rank among the profession where physician and surgeons have the 
highest rate of ADR reporting. Evidence also shows the reason where there was no 
case of ADR publishing among the medical doctors because there was the availability 
of yellow cards and reminders about reporting any form of ADR which led to an 
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increase in reports but over time when verbal discussion were withdrawn, reports 
drastically drop despite continuing availability of yellow cards which suggest that the 
availability of yellow card alone does not guarantee an increase in ADR reporting 
which also show fundamental constraints between attitudinal survey and the need to 
explore a way of making it a cultural attitude towards reporting ADRs(McGettigan et 
al., 2003).  
Another recent research which was carried out in Dublin based teaching hospital 
where ADR actually caused a lot of admission within the hospital which led to 
evaluation of what is actually leading to this problem.(Walsh et al., 2015) 
Recent pharmacovigilance studies have shown very insufficient and inadequate 
prove over the number of the sample size used for the clinical trial study and this has 
been a very huge challenge for the pharmacovigilance practice where most studies 
are dependent on spontaneous reporting of ADRs however, this has resulted in the 
way of reporting ADRs among healthcare professionals and this finally led to not be 
able to gather enough database information on ADR despite the use of electronic 
health records as a source of secondary backup for data.  (Lardon et al., 2015) 
A publication by St James medical hospital in Ireland also discuss extensively the use 
of yellow card ADR reporting as an efficient surveillance system for ADRs during 
clinical practice. This came into reality to be used in the 60s to the disaster that 
occurs in 1968 where the WHO begin the drug monitoring program as a means for 
receiving ADR data from every member state country contributing to improving the 
evaluation of rare and serious adverse reaction(NMIC, 2005)   
2.9 Recommendations for Improvement of Adverse Drug Reaction Reporting  
According to a recent publication on educational intervention to improve the 
attitude, knowledge, and practice of healthcare professionals regarding 
pharmacovigilance in Nigeria where the study aims to evaluate a long term 
messaging reinforcement towards achieving a good pharmacovigilance practice and 
this was carried out at six different teaching hospitals. A total of 40 questions are 
used for the evaluation where a total of 12 questions are related to that of the 
knowledge of the HCP, 10 related to attitudes surrounding ADR reporting and 18 
focusing on ADR practice. After proper research, the result shows that out of 931 
HCP in the cross-sectional study correspondence they got the rate of 77.6% with 
approximately 64.0% for the intervention arm while having 36% at the control 
arm.(Opadeyi et al., 2019) 
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In the case of a pre-intervention study where 811 HCP participated, which shows 
65% are in the intervention arm and 35% are in the control arms. The result has 
shown a level of correlation between the post-intervention study and the post-
intervention surveys even though there was a distinct increase across the level of 
knowledge across different groups while that of intervention group shows that the 
HCP has a high-level knowledge of ADR reporting importance in drug 
monitoring.(Opadeyi et al., 2019) 
Another published research study on the knowledge and attitude of the Healthcare 
Professionals towards Pharmacovigilance and Adverse Drug Reaction Reporting in 
Northern Cyprus where a face to face questionnaire was conducted among 90 
pharmacists, 96 nurses and 71 physicians at the Turkish Republic of Northern Cyprus 
that volunteer to participate in the study. The outcome of the study shows that only 
13% of pharmacists, 2% of nurses and 20% of physicians knew pharmacovigilance. 
While also 32%,12% and 54% of the participants claimed that there is ADR case 
reported from their patients, but 10%  and 3 % of the pharmacist, nurses and 
physician also claimed they report cases of ADR to the concerned organization while 
the common reason given by the participated HCP was lack of knowledge of the 
where/how to report a case of ADR, lack of due time, ADR reporting being not 
mandatory, belief that not part of their responsibility while also avoiding the 
professionalisms of the job. In conclusion, the research shows that HCP has 
insufficient knowledge about pharmacovigilance which needs an extensive training 
program about pharmacovigilance and ADR among HCPs.(Toklu and Soyalan, 2016) 
2.9.1 Conclusion 
After going through all research study of different literature review around the world 
and articles from Nigeria and Ireland, It was finally proving that the challenges facing 
ADR reporting among the HCPs continue to increase with a highly significant rate 
within the developing world and Nigeria as a case study compare to that of Ireland. 
Besides, the need to sustain the effort of pharmacovigilance in Nigeria is very key 
and this can be done by putting in responsible regulatory authorities and health 
organizations to help in reporting. Inadequate knowledge from the literature review 
had been a major challenge facing improvement in the rate of ADR reporting the 
quality of reports. 
Moreover, the assumption of HCP in the hospitals and teaching hospitals in the 
developing country shows that medical doctors are seen as the core HCP leaders of 
the healthcare management and who is responsible for the bulk responsibility of 
reporting any ADR case as they are considered as the primary reporters compare to 
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the others. While in the case of the developed countries where reporting of ADR 
reactions responsibility are considered by both the pharmacist and Medical Doctors, 
although with the higher percentage to that of pharmacists compare to other 
healthcare professionals. Also, the pharmacists are better trained compared to other 
HCP but shy away from their responsibility due to lack of will and cultural attitude 
towards ADR reporting.  
For instance, a community pharmacist in Nigeria tends to have more cases of ADR 
compare to the hospital pharmacist because people tend to easily get prescription 
over the counter medications by simply walking into any community pharmacist 
which led them been able to report more cases of ADR on both existing and new 
drugs compare to the counterpart in the hospital and this will help towards proper 
data coverage and spontaneous reporting of ADRs. 
Furthermore, the findings from different research from above show a high level of 
inadequate knowledge and poor attitude as the main factors affecting the rates of 
ADR reporting  and quality of reports within this two regions. Also, Also from the 
literature from it shows that most tertiary healthcare centres and teaching hospitals 
as seen medical doctors as the leaders of healthcare management which has led to 
the other HCPs thinking the bulk responsibility of reporting ADRs rest on them alone 
as they are always seen as the first within the healthcare sectors . This has led the 
pharmacist to believe their role only lies on dispensing already prescribed drugs 
which end up making them feel less obligated towards ADRs reporting believing is 
the role of the medical doctors. Beside the community pharmacist in both regions 
tend to experience more ADRs reactions because people tend to get prescription 
over the counter by simply walking into any of the nearest pharmacy and scenario is 
highly common within the developing countries and especially Nigeria as a case, 
these pharmacists tend to encounters higher number of ADRs from the old and new 
drugs which will contribute towards spontaneous reporting of ADRs. 
Finally, so as to meet up the recommended optimal target lay down by the WHO of 
200 reports per million population, the need to further strengthen reporting of ADRs 
and effective drug monitoring by overcoming the challenges of lack of knowledge 
among HCPs, slow implementation of policies, ineffective ADR reporting systems and 
models, lack of willingness towards pharmacovigilance, lack of inadequate 
infrastructural healthcare system, lack of government support, no financial support 
to improve ADRs, work hours constraints and poor awareness and knowledge of 
established guidelines and regulations, lack of proper training  and the need for ADR 
specialist to encourage ADR reporting. 
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CHAPTER 3: RESEARCH METHODOLOGY 
3.1 Research Philosophy 
The philosophy behind this research is to be able to aim at explaining the information 
gathered from the respondents which help in giving a concluding study of the 
research. The progress has helped through measurable large numbers of randomly 
selected respondents of healthcare practitioners mostly the medical doctors and 
pharmacists. 
The healthcare practitioners are provided with adequate and well structure 
questionnaires where data are adequately collected, analysed and interpreted 
without any form of human interference or personal opinion or interest and this was 
done using an online Microsoft electronic survey to avoid any form of cross 
interactions with the research participant’s opinion. Also, the qualitative approach 
which covers the phone interviews determined the personal views of the healthcare 
professionals even though it was subjected to the genuity and reliability of the 
representation. However, it was associated with high level experienced healthcare 
practitioners with years of experience in the field which brought the philosophy of 
interpretivism for proper appropriate result oriented. 
3.2 Research Strategy 
The strategy behind the research was to evaluate the knowledge and awareness 
along with the practice of ADR reporting among medical doctors and pharmacist in 
Ireland and Nigeria while comparing the two results of the two countries along with 
the challenges faced by each region towards improving ADR reporting rates and to 
promote long term pharmacovigilance practices within the two regions. The HCPs 
who received the questionnaires was told the reason behind the research is being 
conducted by the author as part of the requirement for the awards of M.Sc. in 
pharmaceutical Business and Technology. The questionnaires were put together in 
an easy way to answer and with familiar medicals terms for respondents' 
understanding. It was administered to members of the pharmacist association of 
Nigeria, Members of University College Hospital across the country while the Ireland 
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3.3 Research Approach 
To have a comparative assessment of current and future pharmacovigilance in the 
developed and developing countries- A case study of Ireland and Nigeria. While 
determining the challenges and factors limiting healthcare professionals from having 
good ADR reporting in both countries, the application of quantitative and qualitative 
research methods will be used (Survey questionnaires and phone interviews). 
The questionnaires were distributed to the HCPs mostly the medical doctors and 
pharmacists through online Microsoft media where they were requested to help 
answer and fill the survey. Using this medium enables the author to gather accurate 
and appropriate information from both countries to help in statistical analysis. The 
questions tend to help determine the general perspective of the different countries 
towards ADR reporting while ascertaining awareness about the old and new ways of 
reporting. Besides, the author was also able to identify the best approach towards 
ADR reporting within the two regions as well the two major classes of the healthcare 
professionals while recommending what is suitable and sustainable over a long term 
period. 
The qualitative approach was conducted using a phone interview to have a better 
understanding about people personal perspective and approach towards ADR in 
Nigeria and Ireland and this was carried out with highly experienced medical doctors 
and pharmacist while asking them questions in related in pharmacovigilance and 
factors they considered challenging and ways of improving ADR reporting within this 
two regions. 
Data collection was done where the analysis was carried out on both groups 
approached and compared to that the research literature findings to show a 
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Section. No Primary Data Part A Part B 
1 Approach Quantitative 
analysis 
Qualitative analysis 
2 Philosophy Positivism Interpretivism 





4 Structure 5 sections made up 
of 20 questions 
5 – 10 minutes of 
phone 
conversations 
5 Subjects (Ireland) Medical Doctors 
(12) 
Pharmacists (35) 
Medical Doctors (1) 
Pharmacists (2) 
6 Subjects (Nigeria) Medical Doctors (32 
 
Pharmacist(43) 
Medical Doctors (2) 
 
Pharmacists (3) 
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3.4 Survey questionnaire for Healthcare professionals: 
The survey questionnaire consisted of 20 questions which are divided into 5 different 
sections to satisfy the purpose of the research for the Nigeria Healthcare settings 
while using the same format for the Ireland Healthcare settings. Comparisons of the 
two results are done using a Microsoft forms app and doing this reinforces the 
credibility of the philosophy of positivism to encourage the respondents towards 
expressing their opinion without any form of interference or hesitation. 
The first paragraph of the question comes with an introduction which was designed 
to gain the consent and credibility of the respondents while asking for their 
permission to use their result for the study. The author also assured them of the 
safety of the data generated from the survey which will be handled by general data 
protection regulation (GDPR). 
3.5 Primary Data Collection  
The questionnaires are structure in a way to give the author the exact research 
objectives without any interference. 
Section 1 is on demographics which consist of five questions in which the 
respondents are giving the option of picking the right one based on their opinion and 
this section is categorized base on the level of the HCP, years of experience and age 
group the HCP fell into. 
Section 2: was to check the level of knowledge of HCP concerning ADR reporting and 
the way the system works both in Nigeria and Ireland with the way of gathering 
information on ADRs knowledge and the method and process of reporting an ADR. 
This covers questions such as awareness in terms reporting, should it be voluntary or 
mandatory towards ADR reporting and the rules and guidelines guiding ADR 
reporting in Nigeria and Ireland. 
Section 3: discussed the awareness of ADR reporting in Ireland and Nigeria which is 
to help us ascertain the level of understanding and awareness of ADRs and 
pharmacovigilance practice in Nigeria and Ireland. Besides, the need to understand 
the frequency at which ADRs are being done and where to submit a report to and 
what mode of submission is being used in both countries.  
Section 4: focuses more on challenges facing ADR reporting in Ireland and Nigeria 
while giving their opinion in respect to these challenges facing adequate reporting in 
pharmacovigilance practice and ADR reporting in both countries. 
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Section 5: These sections tend to do with respondents opinion on providing 
recommendations for HCP within the two countries while agreeing to some terms as 
ways of improving ADR reporting 
3.6 Sources 
The questionnaires were distributed to groups of healthcare professionals over the 
internet using Microsoft form for the one being sent to Nigeria while some others 
are handle by hand to hand distribution within community pharmacy (Boots) in 
Ireland precisely Dublin. A total of 122 participants from both countries which 
comprise of 44 medicals doctors and 78 pharmacists. Also, Microsoft excel sheet was 
used to evaluate the result gotten to produced pie and bar charts to present the 
findings as well as to compare to that of the one gotten from the other country. 
Finally, phone interviews were done with highly experience healthcare professionals 
for a better understanding of the challenges facing ADR reporting in Nigeria and 
Ireland. 
Medical Doctors Selection 
NIGERIA 
The author contacted the Director of Computing and Information Technology at the 
University College Hospital in the person of MR ADETUNJI ADEREMI who also 
happened to be my Uncle. I explained the reason and the purpose of my research to 
him and how he can help use his office to help me share my survey questionnaires. 
Also, I contacted the Nigeria Medical Association through its social media platform 
(Facebook and LinkedIn). As a result, the medical doctor showed a high level of 
response which makes my research a successful one. 
 IRELAND 
The author contacted some of the teaching hospitals in Ireland (St James Hospital, 
Connolly Hospital Blanchardstown and Mater Misericordia University Hospital) 
where the response was low due to the pandemic outbreak disease which most of 
the medical professionals are busy fighting the curse. However, some responses 
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Pharmacists Selection. 
The author reached out to pharmacist students of Nigeria towards getting the survey 
questionnaire and received recommendations from highly experienced pharmacists 
who help towards getting the result while also using the same platform I used in 
getting result for the medical doctors. 
Ireland 
The authors reach out to the community pharmacist and few other pharmacists 
within the hospital settings which he received good positive feedback. 
3.7 Ethical Issues 
A brief explanation of the research study was put on the front cover of the survey 
questionnaires which was provided to the healthcare professionals to have the 
necessary understanding of what the research is all about while they were duly 
informed about the research study as a part of the author requirement for his 
master’s degree program. 
Also, the author makes sure the questionnaire is well structured in a way that no 
personal information of the respondent is needed and all questions are strictly based 
on the research study and objectives. Also, all respondents were duly informed about 
the right to withdraw from participation at any time if they are not confident 
enough. 
3.8 Inclusion and Exclusion Criteria  
The author included an introductory letter to the survey questionnaire which had the 
approval of their informed consent before proceeding which means it was at the 
discretion of the participants to either participate or rather withdraw. The survey 
questions sent through emails and online platforms also contain information about 
voluntary participation. 
However, all healthcare professionals who decided to withdraw or declined to 
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3.9 Conclusion 
The research study was carried out using 20 questions with 5 different sections and 
was based on both quantitative and qualitative approaches across the medical 
doctors and pharmacist which are the key healthcare professionals towards positive 
response. While the qualitative approach involved phone interviews to allow better 
understanding and insights on the research study and the respondents' thoughts. 
The data collected in both countries were analysed and compared to each other both 
in terms of the literature review carried out over the previous research and to better 
ascertain the challenges facing the ADR in the both region while looking at how each 
country can help improve this challenges facing ADR reporting.  


















42 | P a g e  
 
 
CHAPTER 4: FINDINGS AND ANALYSIS 
4.1 Overview 
This section explains the purpose of our research towards tackling the challenges and 
how to improve ADR reporting in the developing countries among HCPs while using 
Nigeria as a case study by analysing the level of knowledge, attitude and experience 
of ADR spontaneous reporting while comparing the results to that of the developed 
countries-a case study of Ireland. Also, the areas that needs improvement within this 
two regions and how our research outcomes can help improve the challenges facing 
the developing countries. The objectives surrounds the investigation of challenges 
affecting effective ADR reports in the developing countries, examine the awareness 
of HCPs obligations towards ADR reporting, review guidelines and regulations and 
finally compare the results of the two stated countries and how they can help 
improve ADRs and Pharmacovigilance within the regions.  
The data generated from our questionnaire and how they are going to be analysed 
accordingly in comparison to each countries data generated. This data assisted the 
author towards knowing the challenges faced by two countries in terms of 
knowledge, awareness, and challenges faced with healthcare professionals towards 
ADR reporting within the two regions while all providing the basis on how the 
improvement can be done within the two countries( Ireland and Nigeria). 
The author conducted a phone interview with highly skilled and experienced medical 
doctors and pharmacists who also help put more suggestions and overlap with the 
share questionnaire results, literature review and their personal views apart from the 
author's views and understanding regarding ADR reporting within the two regions. 
4.2 Demographic Data (Questions 1-4) 
4.2.1 Response Rate: The questionnaire was distributed to 154 healthcare 
professionals in both countries (Ireland and Nigeria), which was distributed equally 
among the healthcare professionals within the two regions consisting of 90 
healthcare profession (45 medical Doctors and 45 Pharmacist) from Nigeria while 
same was done to Ireland consisting of 20 medical doctors and 45 pharmacists.  A 
total of 122 accepted responses were received with a response rate of 79.2%. 
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For Nigeria 
The total participant who responded was 32 medical doctors out of 45 which 19 are 
male and 13 being female. In comparison, a total of 43 respondents are pharmacists 
which the males are 18 and 25 are females. 
Although getting the respondents to do the survey was not easy as I need to be 
sending and posting quick reminder through the entire platform used for sharing the 
questionnaires. The author received more responses once this quick reminder is 
done. 
For Ireland 
The total respondents the author was able to receive were 12 medical doctors out of 
20 which 8 are male and 4 are female. In comparison, a total of 35 respondents were 
pharmacists where will have 23 females and 12 males, respondents. 
4.2.2 Level of experience  
In Nigeria 
Out of the 75 respondent from Nigeria that completed the questionnaires, young 
adults between the age of 18- 30 years predominantly responded well which led to 
the author having a total of 53 within the age group compared to others where 17 
were between the age of 31 to 40, 4 from 41 to 50 and one respondent was 51 years 
and above. 
Also, many of the respondents who are medical doctors 22 and pharmacist 25 who 
participated in the questionnaire had experience 1year to 5years with only three 
medical doctors having an experience of more than 10years. 
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M= Male, F= Female: U=undisclosed 
Table 3: Demographics 
IN IRELAND 
Out of 47 respondents that completed the questionnaire, 27 predominantly between 
the ages of 18 to 30, 15 between the ages of 31 to 40, three respondents aged 
between 41 to 50 and just one 51years and above. 
Also, the medicals doctors that participated in the survey that had experienced 
between 1 to 5 years are 8 while the pharmacist that participated who had 
experienced between the ages of 1 to 5 is 28 with no medical doctor with experience 
















6 - 10 >10 M F U   
Medical 
Doctors 
2 22 5 3 19 13 0 32 out of 45 71.1% 
Pharmacist 8 25 8 2 18 25 0 43 out of 45 95.5% 
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   M= Male, F= Female: U=undisclosed 
   Table 3: Demographics 
4. 3 ADVERSE DRUG REACTION (ADR) REPORTING BASED ON KNOWLEDGE. 
The responses are remarkable which different response opinions.  It shows a positive 
and encouraging outcome based on the knowledge of the respondents. 
Question 5 
The analyses are based on the respondent's knowledge of how to report ADRs in 
Nigeria and Ireland. 
IN NIGERIA:  
From the pie chart below the analysis shows that the participants’ knowledge on 
how to report an ADRs in Nigeria are 71.0% of the total 75 respondents which consist 
of 26 medical doctors and 27 Pharmacist that admitted to the knowledge of ADR 
reporting while 29.0% of respondents (six medical doctors and 16 pharmacists) do 


















6 - 10 >10 M F U   
Medical 
Doctors 
1 8 3 0 8 4 0 12 out of 
20 
60.0% 
Pharmacist 3 28 3 1 12 23 0 35 out of 
45 
87.5% 
46 | P a g e  
 
 
Figure 5a. Knowledge of ADRs among Healthcare Professionals in Nigeria. 
IN IRELAND 
From the pie chart below the analysis shows that the participants’ knowledge on 
how to report an ADRs in Ireland are 98.0% of the total 47 respondents which consist 
of 12 medical doctors and 35 Pharmacist that admitted to the knowledge of ADR 
reporting while 2.0% of respondents (zero medical doctors and one pharmacist) have 
no knowledge on how to report ADRs in Ireland- see figure 5b 
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Figure 5C: Comparison of the knowledge of ADRs report between Nigeria and 
Ireland. 
From our analysis above it shows that both countries have above average knowledge 
among healthcare professionals on how to report ADRs as shown from the survey. 
However, the pharmacists in both countries have overwhelming knowledge than 
their medical doctor’s counterparts as it pertains to ADR reporting. 
Question 6:  
This question serves as a follow up to ascertain the source of their knowledge 
towards ADR reporting within the two regions. 
IN NIGERIA: 
45% of the respondents (13 medical doctors and 21 pharmacists) who admitted to 
getting their source of knowledge for ADR from professional textbooks and journals, 
36% of respondents (12 medical doctors and 15 pharmacists) agreed to get their 
source of knowledge from verbal communication from colleagues, followed with 15% 
( 4 medical doctors and 7 pharmacists) getting their knowledge from newsletters 
from regulatory agencies and lastly the 4% ( 1 medical doctor and 3 pharmacists) 
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Figure 6a Source of Knowledge for reporting ADRs in Nigeria. 
IN IRELAND 
41% of the respondents (5 medical doctors and 14 pharmacists) who admitted to 
getting their source of knowledge for ADR from professional textbooks and journals, 
28% of respondents (4 medical doctors and 11 pharmacists) agreed to get their 
source of knowledge from verbal communication from colleagues, followed with 19% 
( 2 medical doctors and 7 pharmacists) getting their knowledge from newsletters 
from regulatory agencies, 4% ( 1 medical doctor and 3 pharmacists) who admitted to 
getting their knowledge from internet and social media and lastly 1 pharmacist 
admitted in getting their information and knowledge from conference and 
workshops. 
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This two analysis shows that the medical doctors and pharmacists in Ireland and 
Nigeria tend to utilize professional journals and verbal communication more as their 
source of knowledge. In Ireland, the medical doctors and pharmacist tend to go show 
a trend that they get their information on different platforms which bring the 
awareness of their ADR reporting within the region when compare to the Nigeria 
where others claim to their information from NAFDAC newsletters and social media 
and no presence of any conference or workshop. 
Question 7 
To ascertain the source of the knowledge acquire the need to know the organisation 
responsible for handling ADR reporting in Ireland and Nigeria. 
An overwhelming majority 62% respondent (22 medical doctors and 27 pharmacists) 
agreed to identify with the National Agency for Food and Drug Administration and 
Control (NAFDAC), 20% identified with Pharmacist Council of Nigeria which the 
respondent are (4 medical Doctors and 11 pharmacists), 7% respondents( 2 medical 
doctors and 3 pharmacists) identified to Medical and dental council of Nigeria. 11% 
of identified with world health organization which consists of 4 medical doctors and 
2 pharmacists. 
 
   
Figure 7a: Organization responsible for handling pharmacovigilance and ADRs 
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IN IRELAND 
An analysis from the chart below shows an overwhelming outcome with 92% 
respondent ( 8 medical doctors and 32 pharmacists) agreed to identify with the 
Health Products Regulatory Authority (HPRA), 4% Irish Medical Council which the 
respondent is ( 2 medical Doctors only), 4% respondents( 2 medical doctors and 3 
pharmacists) identified to pharmaceutical society of Ireland. 
 
Figure 7b: organisation responsible for handling ADRs in Ireland. 
Comparison of the two results from both regions, As confirmed from the result from 
Nigeria it shows few medical doctors and pharmacist still incorrectly confirm to 
recognizing pharmacist council of Nigeria as the body responsible while an 
overwhelming majority agreed to recognized the NAFDAC body as the primary 
authority for handling pharmacovigilance within the region. In Ireland, the vast 
majority of the medical doctors and pharmacists recognized well with the Health 
Products Regulatory Authority (HPRA) which shows how knowledgeable and 
informed in terms of ADRs reporting compare to that of Nigeria. 
Question 8: 
To ascertain the mode of reporting ADRs in both countries we need to know which 
ADR method the HCP are familiar with. 
IN NIGERIA 
The healthcare professionals in Nigeria ascertain that ADRs methods are carried out 
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of Yellow Card/ADR forms, 25% of respondents (8 medical doctors 11 pharmacists) 
confirmed that ADR E reporting is the method used, 24% respondents (12 medical 
doctors 6 pharmacists) ascertain the method to both yellow cards and ADR E 
reporting.  
   
Figure 8a: Methods familiar to ADR reporting in Nigeria among the HCP. 
IN IRELAND 
The healthcare professionals in Ireland ascertain that ADRs methods are carried out 
with 26% of respondents (3 medical doctors 8 pharmacists) ascertaining to the use of 
Yellow Card/ADR forms, 23% of respondents (3 medical doctors 11 pharmacists) 
confirmed that ADR E reporting is the method used, 51 % respondents (6 medical 
doctors 16 pharmacists) ascertain the method to both yellow cards and ADR E 
reporting. 
 




















Figure 8C: Comparison of the methods of ADRs reporting between Medical Doctors 
and Pharmacist in both countries. 
As shown above it shows that HCP in Ireland are more familiar with using both the 
Online E-ADR reporting form and Yellow Card/ADR forms with majority of the HCPs 
agreeing to this. While in contrast to HCP in Nigeria they seem to be more familiar 
with the use of Yellow Card/ADR forms than every other method available for 
reporting ADRs. In addition, the medical doctors in both regions reporting were 
worse than the pharmacists who tend to be more familiar with reporting of ADR. 
Q 9:  
To ascertain our result from Q8, the need to find out the most important criteria for 
submitting an ADR report in Nigeria. 4.0% of the respondent (1 medical doctor and 2 
pharmacists) went with unusual reactions, 8.0% (2 medical doctors and 4 
pharmacists) of the respondents agreed with criteria related to new products 
reactions, 9.0% (five medical doctors and 2 pharmacists) selected criteria related to 
Life-threatening while 79.0% (24 medical doctors and 35 pharmacists) admitted to 
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Figure 9a: Criteria for submitting an ADR report in Nigeria 
IN IRELAND 
4.0% of the respondent (2 medical doctors) agreed with unusual reactions, 4.0% (1 
medical doctor and 1 pharmacist) of the respondents agreed with criteria related to 
new products reactions, 9.0% (3 medical doctors and 1 pharmacist) selected criteria 
related to Life-threatening while 83.0% (6 medical doctors and 33 pharmacists) 
admitted to the all of the listed options as the important criteria for reporting ADR 
 























All of the above




As depicted from the answers received and chat above from the two regions, it 
shows that higher percentage of the pharmacist and medical doctors identified their 
important criteria to that serious/life-threatening reactions, unusual reactions and 
new drug product reactions as all being important to reporting an ADR in both 
Ireland and Nigeria. 
4.4 Adverse Drug Reaction Reporting based on Awareness and Experience in 
Ireland and Nigeria. (Q10 to19) 
Question 10: 
IN NIGERIA: 
This study is basically to analyse the HCP that is mainly responsible for reporting 
ADRs, 
62% respondents which represent majority of the HCP, 21.0% respondent admitted 
to pharmacist being the main person responsible for ADR reporting, 17.0% 
respondents selected medical doctors. 
 












All of the above
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IN IRELAND 
70% respondents of the respondents admitted to every HCP are responsible for 
reporting ADRs, 6.0% respondent admitted to pharmacist being the main person 
responsible for ADR reporting, 24.0% respondents selected medical doctors. 
 
Figure  10b. Who is mainly responsible for ADRs reporting in Nigeria? 
Comparison: 
From both countries' comparisons, it is interesting to know that both the 
pharmacists and medical doctors within these two regions identified that any HCP 
were equally responsible for reporting ADRs within the two regions. Also, when 
comparing the result of that of the medical doctors and pharmacists within these 
two regions it shows that many pharmacists still believed that the main responsibility 
still lies with their profession alone rather than the pharmacist. 
Question 11: 
An overwhelming 92.0% (30 medical doctors and 39 Pharmacist) of respondents 
agreed that ADR reporting should be compulsory in Nigeria with only 8.0% (2 medical 
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Figure 11a: Should ADR reporting be compulsory or voluntary in Nigeria? 
IN IRELAND 
An overwhelming outcome of 96.0% (10 medical doctors and 31 Pharmacist) of 
respondents agreed that ADR reporting should be compulsory in Ireland with only 
4.0% (2 medical doctors and 5 pharmacists of the respondents suggested to it been 
voluntary. 
 
Figure 11b: Should ADR reporting be either compulsory or voluntary in Ireland? 
Comparison: 
Going by the analysis shown above, it shows that majority of the HCP in both regions 
clearly would opt for ADR reporting to be compulsory like should be part of the 
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Figure 11C: Comparison of the two countries towards compulsory or voluntary ADR 
reporting. 
Question 12 
To determine the level at which ADRs are usually observed among HCP in Nigeria, 
62.0% of the respondents (12 medical doctors and 35 pharmacists) admitted to 
observing ADR within their practice in the past 12 months while 27.0% (12 medical 
doctors and 8 pharmacists) had not observe any case over the past 12 months, 11% 
(8 medical doctors and 2 pharmacists) were unsure maybe they have observe ADRs 
during the past 12 months. 
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IN IRELAND: 
The results in Ireland is very interesting and overwhelming as the level at which ADRs 
are usually observed among HCP in Ireland, 72.0% of the respondents (7 medical 
doctors and 27 pharmacists) admitted to observing ADR within their practice in the 
past 12 months while 28.0% (5 medical doctors and 8 pharmacists) had not observed 
any case over the past 12 months. 
 
Figure 12b: Have you observed ADR within the past 12 months in Ireland. 
Question 13:  
To ascertain our result from previous question, will need to know how many ADRs on 
an average do the HCP observed within same 12 months period.  
IN NIGERIA  
89.0% (26 medical doctors and 41 pharmacists) of the respondents admitted to them 
observing less than 25 ADRs within the past 12 months period while the remaining 
11.0% (6 medical doctors and 2 pharmacists) respondents admitted to observed 25 
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Figure 13a: ADRs observe within 12 months period in Nigeria. 
IN IRELAND  
87.0% (7 medical doctors and 34 pharmacists) of the respondents admitted to them 
observing less than 25 ADRs within the past 12 months period while the remaining 
13.0% (5 medical doctors and 1 pharmacist) respondents admitted to observed 25 
more ADRs within the same period 
 
Figure 13b: Average ADRs observed within the past 12 months in Ireland. 
Comparison: 
From the response from the two regions, it shows there is a high frequency of 
observation of ADRs in both countries among both healthcare professionals. Besides, 
the pharmacist seems to observe higher ADRs in their practice compare to the 
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Question 14:  
The most fascinating thing about the respondents here in Nigeria where 32.0% of 
respondents ( 6 medical doctors and 18 pharmacist)  admitted to only reports ADRs 
within the past 12 months, considering the facts that there was higher number of 
HCPs who had observed ADRs in this same time period. While 63.0% of the 
respondents (24 medical doctors and 23 pharmacist) admitted to not have reported 
any case of ADRs within this same period and lastly 5.0% of the respondents( 2 
medical doctors and 2 pharmacists) were unsure of whether they did report a case or 
not.  
  
14a: Reported an ADR in the past 12 months in Nigeria. 
IN IRELAND 
55.0% of respondents (10 medical doctors and 16 pharmacists) admitted to only 
reports ADRs within the past 12 months, considering the facts that there was higher 
number of HCPs who had observed ADRs in this same time period in Ireland. While 
45.0% of the respondents (2 medical doctors and 19 pharmacists) admitted to not 
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Figure 14b: Reported an ADR in the past 12 months in Ireland 
Comparison: There is a big difference in both country cases in term of ADR reported 
within the past 12 months where Ireland tend to have higher percentage of HCPs 
who had reported more ADR compare to the other region even though the 
percentage is still low while Nigeria had higher percentage of HCPs who admitted to 
not reported any cases of ADR considering the level at which they observe an ADR on 
average within the same period. See figure below 
 
Figure 14C: Comparison by HCPs in both countries towards ADRs reported in the 
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Q15 
From the analysis of number of ADRs reported on the average within the two 
regions. 
IN NIGERIA, 
32.0% of respondents (10 medical doctors and 14 pharmacists) admitted to have 
reported a case of ADR of less than 5 within the time period, 8.0% of respondents (2 
medical doctors and 6 pharmacists) agreed to have reported a case between 6 to 10 
ADRs within same time period, while we have 5.0% respondents (1 medical doctor 3 
pharmacists) who admitted to have a case between 11 to 20 ADRs within same 
period. Surprisingly, an overwhelming outcome of 55.0% of respondents (19 medical 
doctors and 20 pharmacists) did not respond to the question. Moreover, it is 
important to know that no participant admitted to have reported a case more than 
20 within the past 12 months according to the survey. 
 
Figure 15a Average ADRs reported in the past 12 months in Nigeria. 
IN IRELAND: 
An overwhelming results coming from Ireland as 59.0% of respondents (6 medical 
doctors and 21 pharmacists) admitted to have reported a case of ADR of less than 5 
within the time period, 11.0% of respondents (five pharmacists) agreed to have 
reported a case between 6 to 10 ADRs within same time period, while we have 2.0% 
respondents (2 pharmacists) who admitted to have a case between 11 to 20 ADRs 
within same period. Surprisingly, an overwhelming outcome of 28.0% of respondents 
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is important to know that no participant admitted to have reported a case more than 
20 within the past 12 months according to the survey.     
 
Figure 15b: Average ADRs reported in the past 12 months in Ireland. 
Comparison: 
The answers from the two region analysis as seen above shows that HCPs in Ireland 
have less than 5 cases of ADRs compare to the HCPs in Nigeria. In addition, this 
further strengthens the previous result and fact that most HCPs who admitted to 
have submitted less ADR reports within that 12 months compared to the number of 
ADRs observed within that same period. 
Question 16: 
From all our analysis from the observation to the reporting and submission of ADRs 
within this two region, this part tend to help us analysis where this report are been 
submitted to ascertain the previous analysis. 
IN NIGERIA: 
3.0% of the respondents submitted their ADRs to the nearest pharmacovigilance 
centre, 16.0% of the respondents submitted to their professional associations while 
21.0% of the respondents admitted to reporting to the pharmaceutical 
company/Drug Manufacture. Surprisingly, the majority of the HCPs who choose 
60.0% admitted to submitting to other sources which show a high level of disparity in 
the survey which would further be established through phone interviews with well 
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Figure 16a: Who did you submit ADR reports in Nigeria? 
IN IRELAND: 
An overwhelming 62.0% of the respondents (5 medical doctors and 24 pharmacists) 
submitted their ADRs to the nearest pharmacovigilance centre, 23.0% of the 
respondents ( 4 medical doctors and seven pharmacists) submitted to their 
professional associations while 15.0% of the respondents( 2 medical doctors and 5 
pharmacist) admitted to reporting to the pharmaceutical company/Drug 
Manufacture. 
 
Figure 16b: Who did you submit ADR reports in Ireland? 
Comparison: 
 Surprisingly, the majority of the HCPs who choose 62.0% admitted to submitting to 
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knowledgeable they have towards ADRs reporting in Ireland. Also, pharmacists were 
more aware of the National Pharmacovigilance Centre in Ireland compare to the 
HCPs in Nigeria who tend to go with others. See figure below 
 
Figure 16C: Comparison of how HCPs from both countries submit ADR reports. 
Question 17: 
24.0% of the respondents in Nigeria admitted to receiving acknowledgement and 
feedback on every ADR reported while an overwhelming 76.0% of respondents 
admitted to not receiving any feedback or acknowledgement on every reports made 
on ADRs. 
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IN IRELAND: 
68.0% of the respondents (3 medical doctors and 29 pharmacists) in Ireland admitted 
to receiving acknowledgement and feedback on every ADR reported while an 
overwhelming 32.0% of respondents( 9 medical doctors and 6 pharmacists) admitted 
to not receiving any feedback or acknowledgement on every reports made on ADRs. 
See the figure below 
 
Figure 17b: ADR report acknowledgement or feedback in Ireland. 
Comparison: 
From the result from Nigeria, it shows that there is poor acknowledgement and 
follow-up culture among the regulatory authority in charge of handling ADR in 
Nigeria while there is high level of feedback regulatory authorities in Ireland which 
sounds like a good cultural attitude among the regulatory body. 
Question 18: 
This section explains how familiarise are the HCPs towards the guidelines and 
regulations pertaining to ADR reporting between the two regions. 
IN NIGERIA:  
83.0% of the respondents (28 medical doctors and 34 pharmacists) admitted to not 
been familiar with the Nigerian guidelines and regulations pertaining to ADR 
reporting while 17.0% of the respondents (4 medical doctors and 9 pharmacists) who 
were familiar with the guidelines and regulations relating to ADR reporting. See the 
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Figure 18a Nigerian guidelines and regulations for ADR reporting 
IN IRELAND: 
19.0% of the respondents (8 medical doctors and 1 pharmacist) admitted to not been 
familiar with the Ireland guidelines and regulations pertaining to ADR reporting while 
81.0% of the respondents (4 medical doctors and 34 pharmacists) who were familiar 
with the guidelines and regulations relating to ADR reporting 
 
 
Figure 18b: Ireland guidelines and regulations for ADR reporting. 
Comparison: 
Analysis the two results from the two regions shows the medical doctors and 
pharmacists in Nigeria were not familiar with the guidelines and regulations 
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healthcare professionals seems to be familiar to the guidelines and regulations 
governing ADR reporting, the pharmacists edged over the medical doctors in both 
regions in terms of guidelines and regulations pertaining to ADR reporting. 
Question 19: 
To support out analysis towards the attitude of the healthcare professionals towards 
improving their knowledge on ADR reporting in both countries. 
IN NIGERIA:  
As confirmed from the answers, the medical doctors and pharmacists were both 
interested in updating themselves in terms of knowledge about ADR reporting 
despite low level of awareness and guidelines pertaining to ADR in Nigeria. 92.0% of 
the respondents (28 medical doctors and 34 pharmacists) admitted to updating 
themselves while the remaining 8.0% of the respondents (4 medical doctors and one 
pharmacist) would rather not consider that. 
 
 
Figure 19a: Updating Knowledge on Nigerian ADR reporting system among HCPs. 
IN IRELAND: 
Out of the 19.0% respondents who are unfamiliar with the Ireland regulations and 
guidelines pertaining ADR reporting, 78.0% of the respondents which consist of (3 
medical doctors and 4 pharmacists) are ready to update their knowledge while the 
remaining 22.0% of the respondents (1 medical doctor and 1 pharmacist) are not 
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Figure 19b: updating knowledge on Ireland ADR reporting systems. 
4.5 Adverse Drug Reaction (ADR) Reporting-Challenges in Nigeria and Ireland 
(Question 20 i-ix) 
Question 20:  
IN NIGERIA: 
This part helps in analysis the challenges among the HCPs in reporting ADRs in 
Nigeria, options are given to the respondents to best ascertain their opinion in 
related to the subject while the author hope to gain more insightful knowledge and 
position of Medical doctors and Pharmacists in Nigeria on factors that pose as a 
challenge which they either agree, disagree or neutral about it. 
75.0% of the respondents in Nigeria agreed that too busy and no enough time to 
send ADR reports was a factor while 16.0% disagree with 9.0% been neutral about it. 
62.0% of the respondents agreed to complex reporting process in Nigeria is one of 
the major factor, 21.0% are neutral about this with 17.0%  of respondents disagree 
to this. 
82.0% of the respondents agreed to not been able to access ADR report form which 
serves as a challenge for ADR reporting, 12.0% respondents disagreed and 4.0% 
respondents are neutral. 
Surprisingly, 50% of the respondents admitted to the fear of exposure to legal 
liabilities from patients or drug manufacturers while 33.0% are neutral about it, 
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57.0% of the respondents disagree to the concern that ADR report might be wrong, 
29.0% are neutral about this with 19.0%  agreed that concerns of ADR reporting 
might be wrong  a major challenging factor to ADR reporting. 
27.0% of the respondents disagree with the concern of filling an ADR report is an 
unpaid work, 52.0% are neutral to this while 21.0% agreed to the motive of filling an 
ADR report is an unpaid work. 
36.0% of respondents agreed that the level of knowledge acquired make it difficult to 
diagnose ADR reporting while 49.0% of respondents disagreed that the level of 
knowledge does not have effect on ADR reporting and 20.0% of respondents 
remained neutral. 
29.0% of respondents attributed to the fear of negative impact of report and 
disciplinary queries towards colleagues, 52.0% disagreed with 19.0% respondents 
staying neutral. 
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Too busy and no enough time to…
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IN IRELAND 
68.0% of the respondents in Nigeria agreed that too busy and no enough time to 
send ADR reports was a factor while 17.0% disagree with 15.0% been neutral about 
it. 
8.0% of the respondents agreed to complex reporting process in Ireland is one of the 
major factor, 11.0% are neutral about this with 81.0%  of respondents disagree to 
this. 
10.0% of the respondents agreed to not been able to access ADR report form which 
serves as a challenge for ADR reporting, 79.0% respondents disagreed and 11.0% 
respondents are neutral. 
Surprisingly, 8.0% of the respondents admitted to the fear of exposure to legal 
liabilities from patients or drug manufacturers while 13.0% are neutral about it, 
79.0% of the respondents disagree with this. 
87.0% of the respondents disagree to the concern that ADR report might be wrong, 
9.0% are neutral about this with 4.0%  agreed that concerns of ADR reporting might 
be wrong  a major challenging factor to ADR reporting. 
92.0% of the respondents disagree with the concern of filling an ADR report is an 
unpaid work, 4.0% are neutral to this while 4.0% agreed to the motive of filling an 
ADR report is an unpaid work. 
19.0% of respondents agreed that the level of knowledge acquired make it difficult to 
diagnose ADR reporting while 60.0% of respondents disagreed that the level of 
knowledge does not have effect on ADR reporting and 21.0% of respondents 
remained neutral. 
2.0% of respondents attributed to the fear of negative impact of report and 
disciplinary queries towards colleagues, 94.0% disagreed with 4.0% respondents 
staying neutral. See figure below 
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Figure 20b: Challenges among health professional in reporting ADRs reporting in 
Ireland.  
Comparison: 
Assessing the two countries challenges facing ADRs reporting among healthcare 
professionals. From the results above, the three major challenges in Nigeria are: too 
busy and enough time to send an ADR report, complex adverse drug reaction 
reporting and lastly report form not easily accessible. While in Ireland the only major 
challenge they have is being too busy and no enough time to send an ADR report. 
See table below 
 IRELAND NIGERIA 
Too Busy and Enough Time to Send an ADR Report  
Complex ADRs Reporting Processes  
Report Form not Accessible when Needed  
Fear of Exposure to Legal Liabilities from Patient of Drug 
Manufacturer  
Concern That ADR Report Might be Wrong  
Concern That Filling an ADR Report is Extra Unpaid Work  
Level of Clinical Knowledge Makes it Difficult to Diagnose an 
ADR  
Fear of Negative Impact of Report and Disciplinary Queries 
towards Colleagues  
 
Table 20c: Similarities and Differences in Challenges faced by HCPs towards ADRs 
Reporting. 
 
0% 20% 40% 60% 80% 100%
Too busy and no enough time to…
Complex ADR Reporting…
Report form not accessible…
Fear of Exposure to Legal
Concern that ADR report might…
Concern that filling and ADR…
Level of Clinical knowledge…
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4.6 ADVERSE DRUG REACTION REPORTING-RECOMMENDATIONS  
Drawing from the entire dissertation and survey carried out from both side aimed at 
how the respondents can help provides recommendations proposed to be effective 
towards improving ADR reporting within the two countries (Nigeria and Ireland). 
IN NIGERIA 
65.0% of the respondents agreed that pharmacovigilance conferences and 
continuous education will improve awareness towards effective ADR reporting with 
just 26.0% of respondents remaining neutral. 
91.0 of the respondents agreed that including adverse drug reaction reporting 
courses and modules to professional training would be effective towards ADR 
reporting while 9.0% of the respondents decided to be neutral. 
96.0% of the respondents agreed to the review of current regulations to make ADR 
reporting a professional obligation among healthcare professionals while 4.0% are 
neutral about it. 
74.0% of the respondents agreed to incorporate remuneration for every ADR case 
reported to encourage good pharmacovigilance practices among healthcare 
professionals, 12.0 of respondents disagree and 14.0% of the respondents are 
neutral about it. 
97.0% of the respondents agreed to increasing publicity of ADR reports schemes in 
local healthcare journals would be effective towards improving ADR reporting while 
3.0% are neutral about it. 
88.0% of the respondents agreed that establishing an ADR department headed by an 
ADR specialist to encourage drug safety practices in health institution towards ADR 
reporting in Nigeria while 12.0% remained neutral…See figure below 
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Figure 20c: Effective recommendations to improve ADR reporting among 
healthcare professionals In Nigeria 
IN IRELAND 
71.0% of the respondents agreed that pharmacovigilance conferences and 
continuous education will improve awareness towards effective ADR reporting with 
just 23.0% of respondents remaining neutral. 
98.0 of the respondents agreed that including adverse drug reaction reporting 
courses and modules to professional training would be effective towards ADR 
reporting while 2.0% of the respondents decided to be neutral. 
83.0% of the respondents agreed to the review of current regulations to make ADR 
reporting a professional obligation among healthcare professionals while 17.0% are 
neutral about it. 
6.0% of the respondents agreed to incorporate remuneration for every ADR case 
reported to encourage good pharmacovigilance practices among healthcare 
professionals while surprisingly 68.0 of respondents disagree and 26.0% of the 
respondents are neutral about it. 
79.0% of the respondents agreed to increasing publicity of ADR reports schemes in 
local healthcare journals would be effective towards improving ADR reporting while 
21.0% are neutral about it. 
58.0% of the respondents agreed that establishing an ADR department headed by an 
ADR specialist to encourage drug safety practices in health institution towards ADR 
reporting in Nigeria, 4.0% disagree and 38.0% remained neutral. 
0% 20% 40% 60% 80% 100%
Adverse drug reaction reporting
courses and modules included…
Review current regulations to
make ADR reporting a…
Incorporate remuneration for
every ADR case reported to…
Increased publicity about ADR
reporting schemes in local…
Establish an ADR department
headed by an ADR specialist to…
Pharmacovigilance conference








Figure 20d: Effective recommendations to improve ADR reporting among 
healthcare professionals In Ireland. 
 IRELAND NIGERIA 
Adverse Drug Reaction Reporting Courses and Modules Included during 
Professional Training to Improve Knowledge  
Review Current Regulations to Make ADR Reporting A Professional 
Obligation Among Healthcare Professionals  
Incorporate Remuneration for Every ADR Case Reported to Encourage Good 
Pharmacovigilance Practices Among Healthcare P  
Increased Publicity About ADR Reporting Schemes In Local Healthcare 
Journal  
Establish an ADR Department Headed By An ADR Specialist to Encourage 
Drug Safety Practices In Health Institution  
 
Table 20D: Comparison of Effective Recommendations to Improve ADR reporting 







0% 20% 40% 60% 80% 100%
Adverse drug reaction
reporting courses and…
Review current regulations to
make ADR reporting a…
Incorporate remuneration for
every ADR case reported to…
Increased publicity about ADR
reporting schemes in local…
Establish an ADR department
headed by an ADR specialist…
Pharmacovigilance conference
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4.7 Qualitative Analysis: 
4.7.1 Comparison of phone Interview with two highly experienced medical doctors 
from Nigeria and one medical doctor from Ireland (Over 7yrs of experience 
respectively) 
 The author explored the opportunity giving to him by the Director of computing and 
Information technology department at the University College Hospital to reach out to 
two medical doctors (internal consultants) who I then explore their opinion, 
perceptions towards ADR reporting in Nigeria and what can be done in terms of 
challenges faced by medical doctors towards ADRs reporting which their consent for 
the interview was based on an anonymous. 
The two specialists observed an average of 15 ADRs over the past 1 year (12 months) 
but never make any effort of submitting any ADR reports because the once they have 
submitted over the years never had any impact on the management of the patient 
rather they prefer to ignore. Also, they also agreed that they never get feedbacks or 
updates in related to the previous reported cases and while some rather come late 
due to the regulatory inactiveness of ADR reporting in Nigeria. 
Surprisingly, the two medical doctors were not aware of any ADR e-reporting form 
available on the website and only one person is aware of national pharmacovigilance 
situated at the geopolitical zone while only one specialist admitted to having access 
to yellow cards or ADR forms which can be tedious at times getting them from 
Director Office due to protocols.  
More so, the author asked the specialist about the gap observed from the survey 
where most young respondents with less than five years’ experience admitted to 
other option about where they submit their ADR reports. They explained to the fact 
that most young doctors tend to submit to senior colleagues as a result of cultural 
practice among medical practitioner where the hierarchy is a key factor and why 
most young doctors are unaware of their responsibilities to directly report to the 
agency in charge of ADRs. 
Furthermore, the specialists also admitted to the review of the entire process of ADR 
reporting so as to encourage healthcare professionals towards active reporting while 
also recommending more educational programs like seminars within each place and 
the importance of ADR reporting while also making suggestion of incentives to help 
encourage the younger professionals to report ADRs. 
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 The medical doctor from Ireland (Over 5 years of experience) when this was 
discussed with him about the analysis on doctors being too busy and no enough time 
to report an ADR reports as the majority agreed to this from the survey, which he did 
agreed to the analysis while stating that there the responsibility actually lies on the 
pharmacist to report an ADR reaction although agreed that doctors can also report 
any form of ADR. Also, the author ask about if incentives are added maybe it will 
encourage the doctors but the specialist responded with an interestingly answer 
which is far more different from that of the Nigerian Specialist which he states in his 
opinion ‘’this would act as an inducement, and anything involving remuneration 
would compromise integrity which is unethical’’. 
 
4.7.2 Comparison of phone interview with highly experienced pharmacists in 
Nigeria and Ireland (Over 5 to 7years experience). 
The author utilized the same platform he was giving by the head of information and 
technology at the University College Hospital to speak to three experienced 
pharmacists over 45 years above while their opinion on ADRs among Nigerian 
pharmacists which they all gave an impressive answer with the agreement of all the 
information obtained will be under anonymity. 
In Nigeria, the pharmacists all understood the importance of pharmacovigilance and 
have the necessary knowledge of ADRs reporting but admitted to poor performance 
of the practices among colleagues due to most cases observed had been reported 
over time and as a results of no response and feedback from the regulatory 
authorities still makes ADRs under reporting. In addition, they admitted to observing 
ADRs in their respective practices but accepted to never report any case over the 
past 12 months. Also, they are aware of the regulatory authorities responsible for 
handling pharmacovigilance and ADRs. 
Furthermore, the pharmacists also explained the reason behind high rates of ADR 
observed among HCPs in Nigeria which they claim was as a result of easy accessibility 
of drugs in pharmacies where most patients and people can purchase self-
medications without prescription while most pharmacist tend to assume the role of 
the medical doctors due to lesser cost and as a result lead to less report of ADRs 
reporting. Another major controversy is the inaccessibility of the yellow cards when 
needed and unfamiliarity of the ADR E-reporting. 
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They all recommend incentives and awareness to improve ADR reporting while also 
suggestion obligations towards ADRs reporting to improve the attitudes and culture 
among healthcare professionals. 
IN IRELAND 
The author was only able to talk to the community pharmacist due to the present 
pandemic outbreak which they all accepted to more awareness still needs to 
continue and culture obligation need still need to be put in place for effective ADRs 
reporting. 
In comparison, the Ireland pharmacists declined to incentives towards improving 
ADRs among pharmacist as they see this as an inducement which will compromise 
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CHAPTER 5:  CONCLUSIONS  
As from the analysis presented above, it has shown that majority of the medical 
doctors and pharmacists in Nigeria have very low level (average) knowledge of ADR 
reporting in Nigeria compare to healthcare professionals (medical doctors and 
Pharmacists) in Ireland who seems to have a high knowledge of awareness and 
reporting of ADRs. Although, both countries HCPs identify correctly with ADRs and 
the criteria considering in reporting a case whether unusual, serious or new drug 
development reactions. In addition, the need for cultural practice among the HCPs in 
Nigeria towards an effective reporting system while not depending on incentives to 
get a case reported as this will induce the integrity of the report and professionals as 
stated by the Irish Healthcare Professionals. 
However, this brought the need of the role of NAFDAC through the national 
Pharmacovigilance Centre to raise up their responsibility of raising awareness, 
providing and encouraging better drug monitoring and safety practice among the 
HCPs in Nigeria as it is been done with the Health Product  Regulatory Authority of 
Irelands . 
Moreover, the HCPs tend to be well knowledgeable about guidelines and regulations 
concerning ADRs in Ireland compare to HCPs in Nigeria where only few are even 
aware of the availability of ADR E-reporting on the NAFDAC website and this is due to 
negligence of previous reports that has not gotten a feedback or a follow up and this 
has resulted to poor reporting rates in medical doctors and pharmacists who are 
expected to be the primary reporters of ADRs. 
Furthermore, during my phone conversation with the pharmacists they also lay 
emphasis on easy access to drug prescription over the counter as being the major 
factor causing poor ADRs reporting.  
Finally, this study finally lay down the facts that both medical doctors and 
pharmacists challenges are different from each other. Although they tend to agree to 
ADR reporting should be made compulsory in both Nigeria and Ireland while both 
countries recommendation provided both received a high rates for approval among 
both groups of healthcare professionals except the part of incorporation of 
remuneration foe every ADR case reported to encourage good pharmacovigilance 
practices among healthcare profession which the Ireland HCPs are against as they 
see it as an inducement which is unethical rather ADRs reporting should be part our 
every HCPs culture.   
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5.1 The five main research questions: 
Question 1: Are the healthcare professionals aware of ADR reporting system 
methods and their responsibility towards good pharmacovigilance practice in 
Nigeria and Ireland? 
From the study carried out by the author and based on qualitative analysis with 
highly experienced medical doctors and pharmacists, it shows that the HCPs from 
Ireland have a high level of awareness and knowledge compare to their counterparts’ 
professionals from Nigeria who happens to be above average towards ADRs 
reporting within their territory. The Ireland HCPs tend to gain their awareness 
actually varies across professionals textbooks and journals, verbal communication 
among colleagues and Newsletter from regulatory agencies compare the Nigeria 
HCPs who gain their awareness mostly from professional textbooks and journals. 
However, the responsibility of promoting awareness of ADR reporting by the 
National Pharmacovigilance Centre under the structure of National food and drugs 
administration and control (NAFDAC) still shows a high level of gap base on the 
author research compare to their counterparts regulatory authority in Ireland, where 
the majority of the HCPs recognized with the Health Products Regulatory Authority 
even though both HCPs from the region still wanted regular awareness of 
pharmacovigilance programs and getting feedback in order the bridge the gap 
affecting under reporting of ADRs reporting in Nigeria.  
 
Question 2: What factors pose as challenges to ADR reporting in Nigeria and 
Ireland? 
As proven from the quantitative and qualitative analysis carried out from the above 
research, both HCPs from Nigeria and Ireland agreed to the global factors causing 
under reporting which includes inadequate healthcare resources, lack of proper staff 
training, long hours of work with limited staff numbers in healthcare institutions. 
Besides, the inaccessibility of ADR forms when needed by the HCPs from Nigeria 
make it more difficult to encourage ADRs reporting, regulatory failure towards not 
providing feedback on time and the complex reporting process contribute to low 
ADR reports. However, the counterpart HCPs from Ireland are doing better in this 
field even though more still need to be done to be able to achieve an optimum level 
of ADRs reporting within the two regions. 
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3. What is the level of awareness among healthcare professionals in Ireland   and 
Nigeria in relation to ADR announcements? 
The level of awareness among the HCPs in Nigeria is very poor which has resulted in 
under reporting of ADRs. However the National Pharmacovigilance Centre under the 
leadership of the National Agency for Food and Drugs Administration needs to step 
up their awareness promotion in Nigeria so has to cover up the awareness challenges 
faced by the HCPs by providing a well-structured ADR reporting system with an 
established guidelines to make it effective. In Ireland, the HCPs show a high level of 
awareness by recognizing easily with the reporting system and with the regulatory in 
charge of ADRs reporting. 
4.  What are the similarities and differences towards ADRs reporting among HCPs 
in Nigeria and Ireland? 
The major and only similarity the HCPs from both regions agreed on is too busy and 
no enough time to report an ADR case. Besides, the HCPs from Nigeria still attributed 
to other factors that contributed to under reporting among HCPs which includes fear 
of exposure to legal liabilities, concern that filling ADR report is extra unpaid work, 
Concern that ADR report might be wrong.    
 
5. What recommendations would help to improve ADR reporting among healthcare 
professionals in Ireland and Nigeria? 
From the study above, HCPs from both regions attributed to under reporting with 
HCPs having a high stake on this compare to their counterpart HCPs from the other 
region but both end up agreeing to improvement and recommendations that need to 
take place to better improve ADRs reporting. The factors are attributed to poor 
training of staff, limited staff numbers within the community and healthcare 
institutions. Also, the accessibility of ADRs form need to be fixed while having a 
proactive regulatory authority that provide feedback on time, easy ADR reporting 
processes to avoid under reporting among HCPs from both region as against what 
was stated in the study. 
Furthermore, the pharmacists from both region seemingly more knowledgeable than 
the medical doctors from both regions, ADRs reporting regulation and guidelines 
should be review and adequately implemented to improve reporting especially 
within the Nigeria HCPs. Also, both HCPs from Nigeria and Ireland agreed to 
organising conference, continuous training and awareness programs to better 
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improve ADR reporting while proving accessibility of reporting methods to the 
professionals. 
Surprisingly, HCPs from both regions agreed to the review of the current regulations 
pertaining ADR reporting while also making it obligatory among HCPs. Establishment 
of ADR department at every healthcare institution  should be encourage so as to 
foster better drug monitoring and safety within these institutions. Incorporation of 
remuneration for every ADR report submitted was encourage and met by majority of 
the HCPs from Nigeria while the Ireland HCPs disagree and during my phone 
interview to further justify this they all subjected to the fact that it may act as an 
inducement which would compromise the integrity and ethics of the work. While the 
author actually believes that incorporating an incentives may have a side effect on 
the ADR reports in Nigeria considering the regularly observed cases there rather it 
should be in form of recognition and awards rather than financial reimbursements in 
order to improve pharmacovigilance within this two regions and most especially 
Nigeria. 
5.2 Comparing and contrasting of results from both primary and secondary 
research. 
From our study above, it shows that both HCPs from Nigeria and Ireland have an 
above knowledge of ADR reporting which is encouraging when compared to similar 
studies from the author literature review. In addition, both HCPs from the two 
regions are willing to update their knowledge which is highly remarkable as a positive 
attitude and culture towards the subject. However, poor awareness towards 
guidelines and regulations pertaining to ADR reporting and the underutilization of 
the ADR e-reporting form within Nigeria has make it very difficult towards having an 
effective ADR reporting when compare to their counterpart country who have more 
effective ADR reporting system. Although under reporting remain a global challenge 
but varied across regions reason while there is a big disparity among the two 
countries studied and some factors associated with these are inaccessibility of 
reporting methods, lack of awareness and knowledge of ADRs reporting procedures 
which are same to those observed within the two regions and most especially 
Nigeria. The studies are noted in the previous studies of high mobility and mortality 
rates in Nigeria.(Fadare et al., 2011), and that of the knowledge of ADRs reporting 
among HCPs in Ireland.(O’Callaghan et al., 2018) 
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Moreover, this study also shows that Pharmacist are more seen to favourable help 
improve the outcomes regarding ADR reporting than their medical doctors because 
they have better knowledge in relation to ADRs reporting and easily recognized with 
the national pharmacovigilance centre within their regions with better work time and 
less busy schedules compare to medical doctors and this will enable them submit 
ADR reports more often. Although both groups admitted to inaccessibility of 
reporting methods most especially in Nigeria compare to their counterpart in Ireland 
which present as a challenging factor towards good reporting practices.(Oshikoya 
and Awobusuyi, 2009)  
Furthermore, in improving ADRs reporting in Nigeria would greatly help reduce the 
running cost within the healthcare sector and reducing mortality rates as well which 
is related to theme through previous studies so as to encourage more awareness and 
education among the HCPs within this region. However, the regulatory body also 
have a role to play in sensitizing the HCPs towards good pharmacovigilance has the 
developing world are really lacking behind as compare to the western countries. The 
effort of the Health Product Regulatory Authority (HPRA) has been highly 
commendable towards awareness, knowledge resources and e-reporting as an 
alternative on their website. As suggested, HCPs from the both countries still agreed 
on reviewing of the regulations and guidelines guiding ADRs reporting while also 
making it an obligatory for HCPs within the region. While financial incentives as 
suggested sounds as an inducement which will compromise the integrity of the work, 
rather professional recognition could be encourage towards implementing an 
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5.3 Concluding Thoughts 
5.3.1 Contributions and limitations of the Research. 
The research has been moderately adequate having generated data from 
questionnaires from HCPs from two different countries amounting to one hundred 
and twenty-two respondents (75 and 47 respondents from Nigeria and Ireland 
respectively) despite the relatively limited available time and pandemic outbreak 
challenges for the study. Data are generated and analyzed based on our research 
objectives and questions with the use of tables and charts for better interpretation 
and perception. While most research papers focus on just a particular region with a 
single group of healthcare professionals but this research study compared two 
different regions (Nigeria and Ireland) with both medical doctors and pharmacists in 
one study. 
The following limitations are observed during the course of the research which is: 
• A relatively small number of respondents from the HCPs from Ireland compare 
to their counterpart from Nigeria which is understandable to be as a result of 
the pandemic outbreak. 
• There is a small number of responses in terms of highly experienced medical 
doctors and pharmacists within the two regions. 
• Relatively small numbers of highly experienced HCPs were interviewed over 
the phone due to the pandemic outbreak.  
• The personal bias of the respondents and the diverse opinions of a participant 
who failed to answer some questions from some part of the survey could have 
affected the outcomes. 
The author also believes the challenges facing ADR reporting and pharmacovigilance 
among our HCPs differs in Nigeria and Ireland as the level of awareness, level of 
education and economic developments has vastly differed among these two regions 
(Ireland and Nigeria). 
The author contributory factor based on his research and analysis shows that both 
HCPs from Nigeria and Ireland agreed to the response of too busy and no enough 
time to send reports while Nigeria HCPs agreed more on the inaccessibility of ADR 
forms and yellow cards when needed, complex reporting processes and excessively 
work schedules and time pressure on them. Although the study shows above-
average knowledge and positive attitude among HCPs from the both region, more 
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HCPs from Nigeria still shows more disagreeing responses than expected which leave 
us to further research. 
5.3.2 Recommendations 
Further research needs to carried out to cover other healthcare professionals most 
especially the nurses since they represent a critical part of healthcare professionals 
so it has to better improve ADRs reporting while a wide range of numbers of HCPs 
should be considered. The need to also add non-healthcare professionals to improve 
the reports of ADR as some cases are observed outside medical settings which will 
further increase the ADR database in Ireland and Nigeria. 
Also, the need for the regulatory body to learn from the Ireland regulatory system 
(HPRA) as the study shows a considerable understanding, knowledge, and awareness 
among HCPs in this region with a good cultural practice compare to their counterpart 
from Nigeria. 
Besides, the need to address the lack of awareness among HCPs in Nigeria as there is 
a big gap between them and the Ireland HCPs. Since most HCPs from Nigeria 
acknowledge to getting their information and understanding of ADRs reporting from 
professional training, textbooks, or journals with less from regulatory authority 
considering the voluminous resources on their website compare to their counterpart 
HCPs from Ireland which all sources are adequately use to improve their awareness 
and knowledge of ADRs reporting and pharmacovigilance. 
Moreover, the need for healthcare institutions and community pharmacists should 
establish an ADRs specialist within their jurisdiction to better improve the attitudes 
and cultural practice among HCPs within the two regions which will lead to proper 
ADRs database records for ADRs observed. 
Furthermore, the regulatory bodies have potential challenges faced by them which 
the needs for questioning and interview to be carried out to further ascertain the 
challenges faced towards ADRs reporting system and pharmacovigilance model used 
to achieve their purpose. Besides, the need for other professional bodies like Irish 
Medical Council, Pharmaceutical Society of Ireland, the medical and dental council of 
Nigeria, Pharmaceutical Council of Nigeria to all partners with their respective 
regulatory authorities to help advance ADRs and pharmacovigilance to better 
improve pharmacovigilance and ADRs reporting. 
To wrap it up, the need for National Agency for Food and Drugs who oversee the 
National Pharmacovigilance Centre in Nigeria to work with the Health Products 
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Regulatory Authority to better advance pharmacovigilance and ADR reporting in 
Nigeria in areas of awareness, knowledge, spontaneous reporting model and 
advance technology towards improvement in ADRs reporting. 
5. 4 Final Conclusions and Reflexion. 
In concluding the comparative research and analysis on the awareness, knowledge, 
and challenges of ADR reporting among healthcare professionals in Nigeria and 
Ireland, with proper literature review across the globe this has been very helpful 
towards achieving and filling the gaps regarding the perspectives among the two key 
health professionals within the two regions while also creating ways at which ADR 
reporting can be optimally achieved in Nigeria as a case study of developing 
countries. 
However, from the literature review, it shows there is a general global crisis of 
under-reporting rates although above average in the western countries compares to 
the developing countries. This all falls under a general factor which includes lack of 
awareness and knowledge, inadequate resources to identify and observe or report 
potential ADRs. Although, the Nigerian healthcare professionals have an average 
knowledge of ADRs and the criteria needed to report surprisingly they focus more on 
knowledge acquisition rather than its cultural practice and implementation. 
Moreover, the rate of ADR reporting rates significantly continue to lower within the 
developing countries and Nigeria as a whole despite the relatively high rates of 
observation of ADRs in the healthcare institution and this is due to increase in self-
medication and increase in healthcare cost within this region as compared to the 
western countries and Ireland as a country. The need to address the ease of 
purchasing drugs over the counter without proper prescription from the medical 
doctors has facilitated ADR prevalence and lack of stringent laws concerning this has 
resulted in poor implementation of adequate ADRs reporting practices. 
Furthermore, the majority of the medical doctors from both regions cited the 
inaccessibility of yellow cards/ADR forms as when needed and inadequate awareness 
as the factor behind under-reporting of ADRs within them even though these 
responsibilities lie solely on the pharmacist. 
Finally, HCPs from both regions opted for a review of regulatory regulations and 
guidelines pertaining to ADRs reporting by ensuring it becomes a cultural practice 
because the negligence as resulted in an overwhelming unwillingness among medical 
doctors and pharmacists to improve the drug monitoring and drug safety practice. 
The author notes that while both Heath Product Regulatory Agency (HPRA) and 
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National Agency for Food Drug Administration and Control (NAFDAC) have an 
improved website with numerous resources pertaining pharmacovigilance and 
proving E- reporting online, the NAFDAC body in charge of pharmacovigilance in 
Nigeria lacks behind towards educating their healthcare professionals on ADR 
reporting and creating easy processing system along with awareness to ensure these 
are fully effective. The Organisation of seminars and continuous education should 
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 Appendix: Survey Questionnaire 
ADVERSE DRUG REACTION (ADR) REPORTING IN IRELAND: HEALTHCARE 
PROFESSIONALS SURVEY 
Dear Respondent, 
I am Olanrewaju Saheed Jimoh, a post-graduate student of Griffith College Dublin, 
Ireland. As part of the requirements for the Degree of Masters (MSc) in 
Pharmaceutical Business and Technology, I am carrying out a research on 
comparative assessment of current and future pharmacovigilance and Adverse Drugs 
Reactions in developed Countries and developing countries- A case study of Ireland 
and Nigeria. 
Adverse drug reaction is an unwanted and/or harmful reaction experienced by a 
patient following drug therapy. According to the World Health Organisation (WHO), 
it is defined as a response to a medicine which is harmful, unintended and which 
occurs at doses normally used in human for the prevention, diagnosis or treatment 
of diseases, or for the modification of physiological function. 
Adverse Drug reaction reporting is critical in improving pharmacovigilance in 
developing countries. This oversees the science and activities that relates to the 
knowledge, detection, assessment and prevention of adverse events or any drug-
related issue.  
The survey is made up of 5 sections aimed at collecting information on the 
participants’ demographics, knowledge, awareness, challenges and 
recommendations for improvement of ADR in Ireland and how we can use this 
outcomes and survey to improve that of the developing countries. 
The privacy of every participant is highly assured as no response will be linked to any 
participant and will be strictly confidential. All data generated will be handled in line 
with the General Data Protection Regulation (GDPR). 
Thank you for your participation. 
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ADVERSE DRUG REACTION (ADR) REPORTING IN IRELAND: Healthcare Professional 
Survey 
DEMOGRAPHICS 
1. What is your gender? 
     a. Male 
     b. Female 
     c. Prefer not to say 
2. What is your age group? 
     a. 18-30 
     b. 31-40 
     c. 41-50 
     d. 51 and above 
3. Which healthcare professional is completing the survey? 
     a. Medical Doctor 
     b. Pharmacist 
     c. Other  
4. How long have you been practicing in your field? 
     a. Less than a year 
     b. 1 year to 5 years 
     c. 6 years to 10 years 
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ADVERSE DRUG REACTION (ADR) REPORTING 
KNOWLEDGE 
5. Do you know how to report ADRS in Ireland? 
     a. Yes 
     b. No 
6. If yes, what is your source of knowledge for ADR reporting? 
     a. Professional textbook and journals 
     b. Verbal Communication from Colleagues 
     c.  Newsletters from regulatory agencies 
     d. Internet and Social Media 
     e. Conference and Workshops 
7. Which organisation is responsible for pharmacovigilance and handling ADR reports 
in Ireland? 
     a. World Health Organisation 
     b. Health Products Regulatory Authority 
     c. Irish Medical Council (IMC) 
     d. Pharmaceutical Society of Ireland. 
8. Which of the following methods of reporting ADRs in Ireland is familiar to you? 
     a. Yellow Card/ADR forms 
     b. ADR E-reporting form 
     c. Both 
     d. None 
9. In your opinion, which is the most important criteria for submitting an ADR 
reports? 
     a. Unusual reactions 
     b. New drug product reaction 
     c. Serious/Life threatening reactions 
     d. All of the above 
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ADVERSE DRUG REACTION (ADR) REPORTING. 
Please place a tick beside the answer to each question 
AWARENESS  
10. In your opinion, who is mainly responsible for reporting ADRs? 
     a. Medical Doctor 
     b. Pharmacist 
     c. Other healthcare Professional 
     d. All of the above 
11. In your opinion, should ADR reporting be either compulsory or voluntary. 
     a. Compulsory 
     b. Voluntary 
12. Have you observed an adverse drug reaction within your practice in the past 12 
months? 
     a. Yes 
     b. No 
     c. Maybe 
13. If yes, how many ADRs on average have you observe within the same time    
period? 
     a. Less than 25 
     b. 26 to 50 
     c. 51 to 100 
     d. Over 100 
14. Have you reported an ADR in the past 12 months? 
     a. Yes 
     b. No 
     c. Not Sure 
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15. If yes, how many ADR have you reported on average in the same time period? 
     a. Less than 5 
     b. 6 to 10 
     c. 11 to 20 
     d. More than 20 
16. To whom do you submit the adverse drug reaction reports? 
     a. Nearest Pharmacovigilance Centre 
     b. Professional Association 
     c. Pharmaceutical Company/Drug Manufacturer 
     d. Other (please state)……………………………… 
17. Did you receive any acknowledgement or feedback for reporting on ADR? 
     a. Yes 
     b. No 
18. Are you familiar with Ireland regulations and guidelines pertaining to ADR? 
     a. Yes 
     b. No 
19. If No, would you consider updating your knowledge about Ireland ADR reporting 
systems? 
     a. Yes 
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ADVERSE DRUG REACTION (ADR) REPORTING 







20 As a healthcare professional, which of these do you consider as a challenge in 
reporting ADRs? 
• TOO BUSY AND ENOUGH TIME TO SEND AN ADR REPORT (     ) 
• COMPLEX ADR REPORTING PROCESSES (      ). 
• REPORT FORM NOT ACCESSIBLE WHEN NEEDED (     ) 
• FEAR OF EXPOSURE TO LEGAL LIABILITIES FROM PATIENT OR DRUG 
MANUFACTURER. (    ) 
•        CONCERN THAT ADR REPORT MIGHT BE WRONG? (      ) 
•        CONCERN THAT FILLING AN ADR REPORT IS EXTRA UNPAID WORK (     ) 
•        LEVEL OF CLINICAL KNOWLEDGE MAKES IT DIFFICULT TO DIAGNOSE AN ADR (  ) 
• FEAR OF NEGATIVE IMPACT OF REPORT AND DISCIPLINARY QUERIES 
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ADVERSE DRUG REACTION (ADR) REPORTING 






Which recommendation do you consider as effective to improve ADR reporting in 
Ireland? 
• ADVERSE DRUG REACTION REPORTING COURSES AND MODULES INCLUDED 
DURING PROFESSIONAL TRAINING TO IMPROVE KNOWLEDGE (     ) 
• REVIEW CURRENT REGULATIONS TO MAKE ADR REPORTING A PROFESSIONAL 
OBLIGATION AMONG HEALTHCARE PROFESSIONALS. (     ) 
• INCORPORATE REMUNERATION FOR EVERY ADR CASE REPORTED TO 
ENCOURAGE GOOD PHARMACOVIGILANCE PRACTICES AMONG HEALTHCARE 
PROFESSIONALS. (     ) 
• INCREASED PUBLICITY ABOUT ADR REPORTING SCHEMES IN LOCAL 
HEALTHCARE JOURNAL (   ) 
• ESTABLISH AN ADR DEPARTMENT HEADED BY AN ADR SPECIALIST TO 
ENCOURAGE DRUG SAFETY PRACTICES IN HEALTH INSTITUTION (    ) 
 
